Anti-PD-1-Anti-VEGF bispecific antibody, pharmaceutical composition thereof and use thereof

By designing bispecific antibodies against PD-1-anti-VEGF, the problem of difficulty in blocking the binding of VEGFA with VEGFR2 and PD-1 and PD-L1 in the prior art is solved, and effective treatment of tumors is achieved, significantly improving the The therapeutic effect.

WO2024240171A1PCT designated stage expired Publication Date: 2024-11-28SHANGHAI JUNSHI BIOSCIENCES CO LTD

Patent Information

Application Number
PCT/CN2024/094648
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-22
Filing Date
2024-05-22
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

The prior art is difficult to effectively block the binding of VEGFA with VEGFR2 and PD-1 and PD-L1 simultaneously, limiting the efficacy of tumor treatment.

Method used

Develop a bispecific antibody against PD-1-anti-VEGF, which is capable of simultaneously binding VEGF and PD-1, blocking VEGFA binding to VEGFR2 and PD and PD through specific amino acid sequence designs in its heavy and light chain variable regions. The binding of -1 to PD-L1 activates immune response and inhibits tumor angiogenesis.

Benefits of technology

It has achieved efficient binding of VEGF and PD-1, blocked downstream signaling pathways, inhibited tumor cell proliferation and vascular formation, and significantly improved the efficacy of tumor treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024094648_28112024_PF_FP_ABST
    Figure CN2024094648_28112024_PF_FP_ABST
Patent Text Reader

Abstract

The present application provides a bispecific antibody targeting PD-1 and VEGF, and a composition comprising same. Also provided are a nucleic acid molecule encoding the bispecific antibody of the present application, a vector and a host cell for expressing the bispecific antibody of the present application, and therapeutic and diagnostic methods using the antibody or antigen-binding fragment thereof of the present application and the use thereof.
Need to check novelty before this filing date? Find Prior Art

Description

Anti-PD-1-anti-VEGF bispecific antibody, pharmaceutical composition and use thereof

[0001] This application requests the priority of the Chinese patent application filed with the China Patent Office on May 22, 2023, with application number 2023105756067 and invention name “Anti-PD-1-anti-VEGF bispecific antibodies, pharmaceutical compositions thereof and uses thereof”, the entire contents of which are incorporated by reference into this application. Technical Field

[0002] The present application relates to the fields of tumor therapy and immunology, and in particular to an anti-PD-1-anti-VEGF bispecific antibody, a pharmaceutical composition thereof, and uses thereof. Background Art

[0003] Vascular endothelial growth factor (VEGF) is a growth factor that promotes endothelial cell proliferation, angiogenesis, and vascular permeability. It binds to VEGF receptors on the cell surface and exerts its effects by activating tyrosine kinase signaling pathways. Within tumor tissue, tumor cells, tumor-invading macrophages, and mast cells secrete high levels of VEGF, which stimulates tumor vascular endothelial cells in a paracrine manner, promoting endothelial cell proliferation and migration, inducing angiogenesis, and promoting sustained tumor growth. It also increases vascular permeability, triggers fibrin deposition in surrounding tissues, and promotes the infiltration of monocytes, fibroblasts, and endothelial cells. This facilitates tumor stroma formation and the entry of tumor cells into new blood vessels, promoting tumor metastasis. Therefore, inhibiting tumor angiogenesis is considered one of the most promising cancer treatments. The VEGF family includes VEGFA, VEGFB, VEGFC, VEGFD, and placental growth factor (PIGF). VEGF family members have varying affinities for several receptors. VEGFA primarily binds to VEGFR1, VEGFR2, and NRP-1. Currently, there are many humanized monoclonal antibodies targeting human VEGF, especially VEGFA, such as Bevacizumab, which was approved by the U.S. Food and Drug Administration in 2004 for the treatment of various tumors such as non-small cell lung cancer, renal cell carcinoma, cervical cancer, and metastatic colorectal cancer.

[0004] Programmed cell death protein (PD-1), also known as CD279, is a type I transmembrane glycoprotein surface receptor belonging to the CD28 immunoglobulin superfamily. It is ubiquitously expressed on T cells, B cells, and myeloid cells. PD-1 has two natural ligands, PD-L1 and PD-L2. Both PD-L1 and PD-L2 belong to the B7 superfamily and are constitutively or inducibly expressed on the surface membranes of various cells, including non-hematopoietic cells and various tumor cells. PD-L1 is primarily expressed on T cells, B cells, dendritic cells (DCs), microvascular endothelial cells, and various tumor cells. PD-L2 is exclusively expressed on antigen-presenting cells such as DCs and macrophages. The interaction between PD-1 and its ligands inhibits lymphocyte activation, T cell proliferation, and the secretion of cytokines such as IL-2 and IFN-γ. Due to the broad-spectrum anti-tumor prospects and amazing efficacy of PD-1 antibodies, the industry generally believes that antibodies targeting the PD-1 pathway will bring breakthrough progress in the treatment of various tumors: for the treatment of non-small cell lung cancer, renal cell carcinoma, ovarian cancer, melanoma (Homet MB, Parisi G., et al., Anti-PD-1 Therapy in Melanoma. Semin Oncol. 2015 Jun; 42(3): 466-473), lymphoma and anemia (Held SA, Heine A, et al., Advances in immunotherapy of chronic myeloid leukemia CML. Curr Cancer Drug Targets. 2013 Sep; 13(7): 768-74).

[0005] Bifunctional antibodies, also known as bispecific antibodies, are specific drugs that simultaneously target two different antigens. They can be produced through immunoseparation and purification, or obtained through genetic engineering. Currently, many bispecific antibodies developed are in the IgG-scFv format, also known as the Morrison model (1997Coloma MJ, Morrison SL. Design and production of novel tetravalent bispecific antibodies. Nat Biotechnol. Nature Biotechnology, 1997; 15: 159-163). Due to its similarity to naturally occurring IgG, this format has advantages in antibody engineering, expression, and purification and has been proven to be an ideal form of bifunctional antibodies (Miller BR, Demarest SJ, et al., Stability engineering of scFvs for the development of bispecific and multivalent antibodies. Protein Eng Des Sel 2010; 23: 549-57; Fitzgerald J, Lugovskoy A. Rational engineering of antibody therapeutics targeting multiple oncogene pathways. MAbs 2011; 3: 299-309). Currently, there is still a need to develop a bifunctional antibody drug that simultaneously targets PD-1 and VEGF (e.g., VEGFA).

[0006] Summary of the Invention

[0007] The purpose of the present application is to provide an anti-PD-1-anti-VEGF bispecific antibody, a pharmaceutical composition thereof, and its use. The bispecific antibody can simultaneously bind to VEGF and PD-1, block the binding of VEGFA to VEGFR2, and block the binding of PD-1 to PD-L1.

[0008] The first aspect of the present application provides a bispecific antibody comprising a first protein functional region and a second protein functional region; wherein: the first protein functional region is an anti-PD-1 antibody or an antigen-binding fragment thereof, the second protein functional region is an anti-VEGF antibody or an antigen-binding fragment thereof, the anti-VEGF antibody or its antigen-binding fragment comprises a heavy chain variable region, and the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 whose amino acid sequences are shown in SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9, respectively.

[0009] In some embodiments of the present application, the anti-PD-1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region and / or a light chain variable region, and the amino acid sequences of HCDR1, HCDR2 and HCDR3 contained in the heavy chain variable region are respectively selected from the amino acid sequences of HCDR1, HCDR2 and HCDR3 contained in the heavy chain variable region of nivolumab, pembrolizumab, cemipril limab, toripalimab, sintilimab or carrelizumab; the amino acid sequences of LCDR1, LCDR2 and LCDR3 contained in the light chain variable region are respectively selected from the amino acid sequences of LCDR1, LCDR2 and LCDR3 contained in the light chain variable region of nivolumab, pembrolizumab, cemipril limab, toripalimab, sintilimab or carrelizumab.

[0010] In some embodiments of the present application, the anti-PD-1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region and / or a light chain variable region, wherein the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 as shown in amino acid sequences of SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, respectively, and the light chain variable region comprises LCDR1, LCDR2 and LCDR3 as shown in amino acid sequences of SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6, respectively.

[0011] In some embodiments of the present application, the anti-PD-1 antibody or antigen-binding fragment thereof comprises: a heavy chain variable region having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence of SEQ ID NO: 10, and a light chain variable region having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence of SEQ ID NO: 11; and / or the anti-VEGF antibody or antigen-binding fragment thereof comprises: a heavy chain variable region having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence of SEQ ID NO: 12.

[0012] In some embodiments of the present application, the anti-PD-1 antibody or its antigen-binding fragment is selected from Fab, Fab', F(ab')2, Fd, Fv, dAb, complementarity determining region fragment, single domain antibody, single chain antibody, humanized antibody, chimeric antibody or diabody; and / or, the anti-VEGF antibody or its antigen-binding fragment is selected from Fab, Fab', F(ab')2, Fd, Fv, dAb, complementarity determining region fragment, single domain antibody, single chain antibody, humanized antibody, chimeric antibody or diabody.

[0013] In some embodiments of the present application, the first protein functional region is an immunoglobulin, and / or the second protein functional region is a single domain antibody.

[0014] In some embodiments of the present application, the first protein functional region is an immunoglobulin, and the immunoglobulin is selected from IgG, IgA, IgD, IgE or IgM; preferably IgG.

[0015] In some embodiments of the present application, the first protein functional region is an immunoglobulin, and the constant region of the immunoglobulin is derived from a human antibody; preferably, the constant region of the immunoglobulin is selected from the constant region of human IgG1, IgG2, IgG3 or IgG4.

[0016] In some embodiments of the present application, the first protein functional region is an immunoglobulin, and the second protein functional region is a single domain antibody; there are two single domain antibodies, and one end of each of the single domain antibodies is respectively connected to the C-terminus or N-terminus of the two heavy chains of the immunoglobulin; or one end of each of the single domain antibodies is respectively connected to the C-terminus or N-terminus of the two light chains of the immunoglobulin; or the N-terminus of each of the single domain antibodies is respectively connected to the C-terminus of the heavy chain constant region CH1 of the immunoglobulin, and the C-terminus of each of the single domain antibodies is respectively connected to the N-terminus of the heavy chain constant region CH2 of the immunoglobulin.

[0017] In some embodiments of the present application, the bispecific antibody is selected from the following forms: (1) the first polypeptide chain of the bispecific antibody is represented by the formula VLPD-1-CL, and the second polypeptide chain is represented by the formula VHVEGF-linker-VHPD-1-CH1-hinge-CH2-CH3; or (2) the first polypeptide chain of the bispecific antibody is represented by the formula VLPD-1-CL, and the second polypeptide chain is represented by the formula VHPD-1-CH1-hinge-CH2-CH3-linker-VHVEGF; or (3) the first polypeptide chain of the bispecific antibody is represented by the formula VLPD-1-CL, and the second polypeptide chain is represented by the formula VHPD-1-CH1-linker-VHVEGF-linker-hinge-CH2-CH3; or (4) the first polypeptide chain of the bispecific antibody is represented by the formula VHVEGF-linker-VLPD-1-CL, and the second polypeptide chain is represented by the formula VHPD-1-CH1-hinge-CH2-CH3.

[0018] In some embodiments of the present application, the bispecific antibody is selected from the following: (1) the first polypeptide chain comprises the amino acid sequence shown in SEQ ID NO: 13, and the second polypeptide chain comprises the amino acid sequence shown in SEQ ID NO: 14; or (2) the first polypeptide chain comprises the amino acid sequence shown in SEQ ID NO: 13, and the second polypeptide chain comprises the amino acid sequence shown in SEQ ID NO: 15; or (3) the first polypeptide chain comprises the amino acid sequence shown in SEQ ID NO: 13, and the second polypeptide chain comprises the amino acid sequence shown in SEQ ID NO: 16; or (4) the first polypeptide chain comprises the amino acid sequence shown in SEQ ID NO: 17, and the second polypeptide chain comprises the amino acid sequence shown in SEQ ID NO: 18.

[0019] The second aspect of the present application provides an isolated nucleic acid molecule encoding the bispecific antibody described in the first aspect of the present application.

[0020] The third aspect of the present application provides a vector comprising the isolated nucleic acid molecule described in the second aspect of the present application.

[0021] The fourth aspect of the present application provides a host cell comprising the isolated nucleic acid molecule described in the second aspect of the present application, or the vector described in the third aspect of the present application.

[0022] The fifth aspect of the present application provides a method for preparing the bispecific antibody described in the first aspect of the present application, which comprises the steps of culturing the host cell described in the fourth aspect of the present application, and obtaining the bispecific antibody from the culture.

[0023] The sixth aspect of the present application provides a conjugate comprising the bispecific antibody described in the first aspect of the present application and a conjugated portion, wherein the conjugated portion is a therapeutically active substance or a detectable label; preferably, the therapeutically active substance is a cytotoxin, a cytokine or a radionuclide; preferably, the detectable label is selected from a radioactive isotope, a fluorescent substance, a luminescent substance, a colored substance or an enzyme.

[0024] In the seventh aspect, the present application provides a kit comprising the bispecific antibody described in the first aspect of the present application, or the conjugate described in the sixth aspect of the present application; preferably, the kit further comprises a second antibody, which can specifically bind to the bispecific antibody; preferably, the second antibody further comprises a detectable label, more preferably, the detectable label is selected from a radioactive isotope, a fluorescent substance, a luminescent substance, a colored substance or an enzyme.

[0025] The eighth aspect of the present application provides use of the bispecific antibody described in the first aspect of the present application in preparing a kit; preferably, the kit is used to detect the presence or level of VEGF and / or PD-1 in a sample.

[0026] The ninth aspect of the present application provides a pharmaceutical composition comprising the bispecific antibody described in the first aspect of the present application or the conjugate described in the sixth aspect of the present application; preferably, the pharmaceutical composition further comprises a pharmaceutically acceptable excipient.

[0027] The tenth aspect of the present application provides use of the bispecific antibody described in the first aspect of the present application, or the conjugate described in the sixth aspect of the present application, or the pharmaceutical composition described in the ninth aspect of the present application in the preparation of a drug for preventing and / or treating malignant tumors.

[0028] In an eleventh aspect, the present application provides a method for treating or ameliorating a malignant tumor, comprising administering the bispecific antibody of the first aspect of the present application, the conjugate of the sixth aspect of the present application, or the pharmaceutical composition of the ninth aspect of the present application to a patient in need thereof; the present application also provides the bispecific antibody of the first aspect, the conjugate of the sixth aspect of the present application, or the pharmaceutical composition of the ninth aspect of the present application for treating or ameliorating a malignant tumor; wherein the malignant tumor is a tumor overexpressing PD-L1 and / or VEGF; preferably, the malignant tumor is a solid tumor; more preferably, the malignant tumor is lung cancer, colon cancer, colorectal cancer (CRC), melanoma, or ovarian cancer; more preferably, the lung cancer is non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC); more preferably, the non-small cell lung cancer is squamous non-small cell lung cancer or non-squamous non-small cell lung cancer (nsq-NSCLC); more preferably, the non-squamous non-small cell lung cancer is locally advanced or metastatic nsq-NSCLC.

[0029] The twelfth aspect of the present application provides a method for regulating immune response and regulating tumor angiogenesis, which comprises administering the bispecific antibody described in the first aspect of the present application, or the conjugate described in the sixth aspect of the present application, or the pharmaceutical composition described in the ninth aspect of the present application to a patient in need; preferably, the regulating immune response is achieved by blocking the binding of PD-1 to its receptor, and the regulating tumor angiogenesis is achieved by blocking the binding of VEGF to its receptor.

[0030] The thirteenth aspect of the present application provides the use of the bispecific antibody described in the first aspect of the present application, the conjugate described in the sixth aspect of the present application, or the pharmaceutical composition described in the ninth aspect of the present application in the preparation of the following drugs or reagents: a reagent for detecting the VEGF level in a sample.

[0031] A fourteenth aspect of the present application provides an in vitro method for non-diagnostic and non-therapeutic purposes, comprising the step of administering to cells an effective amount of the bispecific antibody according to the first aspect of the present application, the conjugate according to the sixth aspect of the present application, or the pharmaceutical composition according to the ninth aspect of the present application, wherein the method is selected from the following:

[0032] (1) a method for detecting the level of VEGF in a sample, or a method for blocking the binding of VEGF to VEGFR, or a method for downregulating the activity or level of VEGF, or a method for relieving the stimulatory effect of VEGF on vascular endothelial cell proliferation, or a method for inhibiting vascular endothelial cell proliferation, or a method for blocking tumor angiogenesis; and / or

[0033] (2) Methods for blocking the binding of PD-1 to PD-L1, or methods for downregulating the activity or level of PD-1, or methods for relieving the immune suppression of the body by PD-1, or methods for promoting the secretion of IFN-γ in T lymphocytes, or methods for promoting the secretion of IL-2 in T lymphocytes.

[0034] Beneficial effects of this application:

[0035] The bispecific antibody provided in the present application has good thermal stability and long-term stability, can specifically bind to VEGFA, and can effectively block the binding of VEGFA to VEGFR2, specifically relieving the immune suppression and angiogenesis-promoting effects of VEGFA; can specifically bind to PD-1, and can effectively block the binding of PD-1 to PD-L1, specifically relieving the immune suppression of PD-1, activating the immune response, and having a good effect in inhibiting tumor proliferation.

[0036] Of course, it is not necessary to achieve all the advantages described above at the same time when implementing any product or method of the present application. BRIEF DESCRIPTION OF THE DRAWINGS

[0037] In order to more clearly illustrate the embodiments of the present application or the technical solutions in the prior art, the following briefly introduces the drawings required for use in the embodiments or the description of the prior art. Obviously, the drawings described below are only some embodiments of the present application. For ordinary technicians in this field, other embodiments can also be obtained based on these drawings.

[0038] FIG1 is a schematic structural diagram of DotAb4;

[0039] Figure 2a is a schematic diagram of the structure of antibody 23; Figure 2b is a schematic diagram of the structure of antibody 24; Figure 2c is a schematic diagram of the structure of antibody 27; Figure 2d is a schematic diagram of the structure of antibody 28;

[0040] Figure 3a is a graph showing the binding and dissociation curves of antibody JS001 and human PD-1; Figure 3b is a graph showing the binding and dissociation curves of antibody 23 and human PD-1; Figure 3c is a graph showing the binding and dissociation curves of antibody 24 and human PD-1; Figure 3d is a graph showing the binding and dissociation curves of antibody 27 and human PD-1; and Figure 3e is a graph showing the binding and dissociation curves of antibody 28 and human PD-1.

[0041] Figure 4a is a graph showing the binding and dissociation curves of antibody DotAb4 and human VEGFA; Figure 4b is a graph showing the binding and dissociation curves of antibody 23 and human VEGFA; Figure 4c is a graph showing the binding and dissociation curves of antibody 24 and human VEGFA; Figure 4d is a graph showing the binding and dissociation curves of antibody 27 and human VEGFA; and Figure 4e is a graph showing the binding and dissociation curves of antibody 28 and human VEGFA.

[0042] Figure 5a is a graph showing the simultaneous binding of antibody 27 to human PD-1 and human VEGFA in the test sample group; Figure 5b is a graph showing the nonspecific binding of human VEGFA to human PD-1 in the negative control group; and Figure 5c is a graph showing the nonspecific binding of human VEGFA to JS001 in the negative control group.

[0043] Figure 6a is an ELISA curve diagram of the binding of antibody 23 and antibody 24 to human PD-1; Figure 6b is an ELISA curve diagram of the binding of antibody 27 and antibody 28 to human PD-1;

[0044] Figure 7a is an ELISA curve diagram of the binding of antibodies 23 and 24 to human VEGFA; Figure 7b is an ELISA curve diagram of the binding of antibodies 27 and 28 to human VEGFA;

[0045] Figure 8a is a graph showing competitive inhibition of antibodies 23 and 24 in blocking human VEGFR2 and VEGFA by ELISA; Figure 8b is a graph showing competitive inhibition of antibodies 27 and 28 in blocking human VEGFR2 and VEGFA by ELISA;

[0046] Figure 9a is a graph showing the competitive inhibition of antibodies 23 and 24 in blocking human PD-L1 and PD-1 by ELISA; Figure 9b is a graph showing the competitive inhibition of antibodies 27 and 28 in blocking human PD-L1 and PD-1 by ELISA;

[0047] Figure 10a is a graph showing the activity detection results of antibodies 23 and 24 in the PD-1 / PD-L1 luciferase reporter gene system; Figure 10b is a graph showing the activity detection results of antibodies 27 and 28 in the PD-1 / PD-L1 luciferase reporter gene system;

[0048] Figure 11a is a graph showing the activity detection results of the luciferase reporter gene system in which antibodies 23 and 24 block VEGF-induced NFAT signals; Figure 11b is a graph showing the activity detection results of the luciferase reporter gene system in which antibodies 27 and 28 block VEGF-induced NFAT signals;

[0049] Figure 12a shows the experimental results of antibodies 23 and 24 inhibiting VEGFA-induced HUVEC cell proliferation; Figure 12b shows the experimental results of antibodies 27 and 28 inhibiting VEGFA-induced HUVEC cell proliferation;

[0050] Figure 13a shows the experimental results of the antibody promoting the secretion of the cytokine IL2 in the mixed lymphocyte reaction of donor 1; Figure 13b shows the experimental results of the antibody promoting the secretion of the cytokine IL2 in the mixed lymphocyte reaction of donor 2; Figure 13c shows the experimental results of the antibody promoting the secretion of the cytokine IFN-γ in the mixed lymphocyte reaction of donor 1; Figure 13d shows the experimental results of the antibody promoting the secretion of the cytokine IFN-γ in the mixed lymphocyte reaction of donor 2;

[0051] Figure 14 shows the inhibitory effect of the test substance on the B-PD-1 humanized mouse transplanted MC38 tumor model;

[0052] FIG15 is a graph showing the inhibitory effect of the test substance on the A375 tumor model transplanted in NDG mice.

[0053] TAB001 in the drawings of this application is JS001. DETAILED DESCRIPTION

[0054] The present application is illustrated by the following examples, but is not intended to limit the present application in any way. The present application has been described in detail herein, and its specific embodiments are also disclosed. It will be apparent to those skilled in the art that various changes and modifications can be made to the specific embodiments of the present application without departing from the spirit and scope of the present application.

[0055] Unless otherwise indicated, scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. Furthermore, the laboratory procedures for cell culture, molecular genetics, nucleic acid chemistry, and immunology used herein are conventional procedures widely used in the relevant fields. To facilitate a better understanding of this application, definitions and explanations of relevant terms are provided below.

[0056] VEGF in this application specifically refers to VEGFA. The anti-VEGF antibodies in this application specifically bind to VEGFA and can effectively block the binding of VEGFA to VEGFR2. In some embodiments, VEGFA can be VEGFA from primates (rhesus monkeys, cynomolgus monkeys, or humans), and in some embodiments, VEGFA can be mouse VEGFA.

[0057] As used in this application, when referring to the amino acid sequence of VEGFA protein (GenBank ID: NP_001165097.1), it includes the full length of VEGFA protein, and also includes fusion proteins of VEGFA, such as fragments fused with the Fc protein fragment (mFc or hFc) of mouse or human IgG. However, it is understood by those skilled in the art that mutations or variations (including but not limited to substitutions, deletions and / or additions) can be naturally produced or artificially introduced into the amino acid sequence of VEGFA protein without affecting its biological function. Therefore, in this application, the term "VEGFA protein" should include all such sequences, including natural or artificial variants thereof. Furthermore, when describing a sequence fragment of VEGFA protein, it also includes the corresponding sequence fragments in its natural or artificial variants. In one embodiment of the present application, the amino acid sequence of the VEGFA protein is shown in SEQ ID NO: 19 (excluding the terminal His, the VEGFA protein used in the examples of this application was purchased from ARCO, name: Human VEGF165 Protein, His Tag, product number: VE5-H5248, batch number: 2410-2069F1-146).

[0058] As used in this application, when referring to the amino acid sequence of VEGFR2 protein (KDR) (GenBank ID: NP_002244), it includes the full length of the VEGFR2 protein, or the extracellular fragment VEGFR2-ECD of VEGFR2 or a fragment comprising VEGFR2-ECD; it also includes a fusion protein of VEGFR2-ECD, such as a fragment fused to the Fc protein fragment (mFc or hFc) of mouse or human IgG. However, it is understood by those skilled in the art that mutations or variations (including but not limited to substitutions, deletions and / or additions) may be naturally or artificially introduced into the amino acid sequence of the VEGFR2 protein without affecting its biological function. Therefore, in this application, the term "VEGFR2 protein" shall include all such sequences, including natural or artificial variants thereof. Furthermore, when describing a sequence fragment of a VEGFR2 protein, it also includes the corresponding sequence fragments in its natural or artificial variants. In one embodiment of the present application, the amino acid sequence of VEGFR2 is shown in SEQ ID NO: 20 (the VEGFR2 protein used in the examples of this application was purchased from Sino Biological, name: VEGFR2 / KDR Protein, Human, Recombinant (His Tag), Biotinylated, Cat: 10012-H08H-B).

[0059] As used in this application, unless otherwise specified, the VEGFRs are VEGFR1 and / or VEGFR2; their specific protein sequences are known in the art and can be found in existing literature or GenBank. For example, VEGFR1 (VEGFR1, NCBI Gene ID: 2321) and VEGFR2 (VEGFR2, NCBI Gene ID: 3791).

[0060] As used in this application, when referring to the amino acid sequence of PD-1 protein (Programmed cell death protein 1, NCBI GenBank: NM_005018), it includes the full length of PD-1 protein, or the extracellular fragment PD-1ECD of PD-1 or a fragment containing PD-1ECD; it also includes a fusion protein of PD-1ECD, such as a fragment fused with the Fc protein fragment (mFc or hFc) of mouse or human IgG. However, those skilled in the art understand that mutations or variations (including but not limited to substitutions, deletions and / or additions) can be naturally produced or artificially introduced into the amino acid sequence of PD-1 protein without affecting its biological function. Therefore, in this application, the term "PD-1 protein" should include all such sequences, including natural or artificial variants thereof. Furthermore, when describing a sequence fragment of the PD-1 protein, it also includes the corresponding sequence fragments in its natural or artificial variants.

[0061] As used in this application, the term EC 50 It refers to the concentration for 50% of maximal effect, which is the concentration that can cause 50% of the maximum effect.

[0062] As used in this application, the term "antibody" refers to an immunoglobulin molecule typically composed of two pairs of polypeptide chains, each pair having a "light" (L) chain and a "heavy" (H) chain. Generally speaking, a heavy chain can be understood as the larger molecular weight polypeptide chain in an antibody, while a light chain refers to the smaller molecular weight polypeptide chain in an antibody. Light chains can be classified as kappa and lambda light chains. Heavy chains are generally classified as μ, δ, γ, α, or ε, and define the antibody isotype as IgM, IgD, IgG, IgA, and IgE, respectively. Within light and heavy chains, the variable and constant regions are connected by a "J" region of approximately 12 or more amino acids, and heavy chains also contain a "D" region of approximately 3 or more amino acids. Each heavy chain is composed of a heavy chain variable region (VH) and a heavy chain constant region (CH). The heavy chain constant region is composed of three domains (CH1, CH2, and CH3). Each light chain is composed of a light chain variable region (VL) and a light chain constant region (CL). The light chain constant region consists of one domain, CL. The constant region of an antibody mediates the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system. The VH and VL regions can also be subdivided into highly variable regions, called complementarity-determining regions (CDRs), interspersed with more conserved regions called framework regions (FRs). Each VH and VL consists of three CDRs and four FRs arranged from the amino terminus to the carboxyl terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions (VH and VL) of each heavy chain / light chain pair form the antibody binding site. The assignment of amino acids to each region or domain follows the definition of Kabat Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md. (1987 and 1991)), or Chothia & Lesk (1987) J. Mol. Biol. 196: 901-917; Chothia et al. (1989) Nature 342: 878-883. In particular, the heavy chain can also contain more than 3 CDRs, for example 6, 9 or 12. For example, in the bifunctional antibody of the present application, the heavy chain can be the C-terminus of the heavy chain of an IgG antibody connected to the ScFv of another antibody, in which case the heavy chain contains 9 CDRs. The term "antibody" is not limited to any particular method for producing antibodies. For example, it includes, in particular, recombinant antibodies, monoclonal antibodies and polyclonal antibodies. The antibodies can be of different isotypes, for example, IgG (eg, IgG1, IgG2, IgG3, or IgG4 subtypes), IgAl, IgA2, IgD, IgE, or IgM antibodies.

[0063] As used in this application, the term "antigen-binding fragment" of an antibody refers to a polypeptide comprising a fragment of a full-length antibody that retains the ability to specifically bind to the same antigen to which the full-length antibody is bound, and / or competes with the full-length antibody for specific binding to the antigen, which is also referred to as an "antigen-binding portion". See generally, Fundamental Immunology, Ch. 7 (Paul, W., ed., 2nd ed., Raven Press, NY (1989), which is incorporated herein by reference in its entirety for all purposes. Antigen-binding fragments of an antibody can be produced by recombinant DNA technology or by enzymatic or chemical cleavage of an intact antibody. In some cases, antigen-binding fragments include Fab, Fab', F(ab')2, Fd, Fv, single-domain antibodies (sdAb) and complementary determining region (CDR) fragments, single-chain antibodies (e.g., scFv), chimeric antibodies, diabodies, and polypeptides comprising at least a portion of an antibody sufficient to confer specific antigen-binding ability to a polypeptide.

[0064] As used in this application, the term "Fd fragment" means an antibody fragment consisting of the VH and CH1 domains; the term "Fv fragment" means an antibody fragment consisting of the VL and VH domains of a single arm of an antibody; the term "dAb fragment" means an antibody fragment consisting of the VH domain (Ward et al., Nature 341:544-546 (1989)); the term "Fab fragment" means an antibody fragment consisting of VL, VH, CL and CH1 domains; the term "F(ab')2 fragment" means an antibody fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region.

[0065] In some cases, the antigen-binding fragment of an antibody is a single-chain antibody (e.g., scFv), in which the VL and VH domains are paired to form a monovalent molecule by a linker that enables them to be produced as a single polypeptide chain (e.g., see Bird et al., Science 242:423-426 (1988) and Huston et al., Proc. Natl. Acad. Sci. USA 85:5879-5883 (1988)). Such scFv molecules can have the general structure: NH2-VL-linker-VH-COOH or NH2-VH-linker-VL-COOH. Suitable prior art linkers consist of repeated GGGGS amino acid sequences or variants thereof. For example, a linker having the amino acid sequence (GGGGS)4 can be used, but variants thereof can also be used (Holliger et al. (1993), Proc. Natl. Acad. Sci. USA 90:6444-6448). Other linkers that can be used in the present application are described by Alfthan et al. (1995), Protein Eng. 8:725-731, Choi et al. (2001), Eur. J. Immunol. 31:94-106, Hu et al. (1996), Cancer Res. 56:3055-3061, Kipriyanov et al. (1999), J. Mol. Biol. 293:41-56 and Roovers et al. (2001), Cancer Immunol.

[0066] In some cases, the antigen-binding fragment of an antibody is a diabody, i.e., a bivalent antibody in which the VH and VL domains are expressed on a single polypeptide chain, but with a linker that is too short to allow pairing between the two domains on the same chain, thereby forcing the domains to pair with the complementary domains of another chain and create two antigen-binding sites (see, e.g., Holliger P. et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993), and Poljak RJ et al., Structure 2:1121-1123 (1994)).

[0067] Antibody antigen-binding fragments (e.g., those described above) can be obtained from a given antibody using conventional techniques known to those skilled in the art (e.g., recombinant DNA techniques or enzymatic or chemical cleavage methods) and screened for specificity in the same manner as for intact antibodies.

[0068] In this application, unless the context clearly indicates otherwise, when referring to the term "antibody", it includes not only intact antibodies, but also antigen-binding fragments of antibodies.

[0069] As used in this application, the term "single-domain antibody" (sdAb), also known as "nanobody", "single domain antibody", "single variable domain on a heavy chain antibody", "VHH", "nanobody" and "heavy chain antibody (HcAb)", has the meaning commonly understood by those skilled in the art, which refers to an antibody fragment consisting of a single monomeric variable antibody domain (e.g., a single heavy chain variable region), usually derived from the variable region of a heavy chain antibody (e.g., a camelid antibody or a shark antibody). Typically, a nanobody consists of four framework regions and three complementarity determining regions, with a structure of FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. A nanobody can be truncated at the N-terminus or C-terminus so that it contains only part of FR1 and / or FR4, or lacks one or two of those framework regions, as long as it substantially retains antigen binding and specificity.

[0070] The DotAb described in this application is a single-domain antibody that binds to VEGF (anti-VEGF), and reference can be made to the single-domain antibody that specifically binds to VEGFA described in patent CN117242092A. In some embodiments, the DotAb comprises the CDRs of the VEGFA-binding single-domain antibody described in CN117242092A, or comprises CDRs derived from the VEGFA-binding single-domain antibody described in CN117242092A. In some embodiments, the DotAb comprises the CDRs, FRs, and / or complete amino acid sequence of a VEGFA-binding single-domain antibody selected from 16C2.1 and 21A5.1, such as the HCDR1, HCDR2, and HCDR3 set forth in SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9 in this application. In some embodiments, DotAb is a single-domain antibody having the sequence set forth in SEQ ID NO: 12 herein or a derivative thereof, wherein the derivative sequence is at least 85%, 90%, 91%, 92%, 93%, 95%, 96%, 97%, 98%, or 99% identical or identical to the sequence set forth in SEQ ID NO: 12 herein. DotAb4 is a single-domain antibody with an Fc linked to it, referred to as a heavy chain antibody. DotAb4 may comprise two identical polypeptide chains, each of which has a structure as shown in the formula DotAb-hinge-CH2-CH3, and a schematic structural diagram thereof is shown in FIG1 .

[0071] As used in this application, the terms "monoclonal antibody" and "monoclonal antibody" refer to an antibody or an antibody fragment from a group of highly homologous antibody molecules, that is, a group of identical antibody molecules except for possible spontaneous natural mutations. Monoclonal antibodies have high specificity for a single epitope on an antigen. Polyclonal antibodies are relative to monoclonal antibodies and generally contain at least two or more different antibodies, which generally recognize different epitopes on an antigen. Monoclonal antibodies can generally be obtained using the hybridoma technology first reported by Kohler et al. (Nature, 256:495, 1975), but can also be obtained using recombinant DNA technology (see, for example, USP 4,816,567).

[0072] As used herein, the term "chimeric antibody" refers to an antibody in which a portion of its light chain and / or heavy chain is derived from one antibody (which may be derived from a particular species or belong to a particular antibody class or subclass), and another portion of its light chain and / or heavy chain is derived from another antibody (which may be derived from the same or different species or belong to the same or different antibody class or subclass), but in any case, it still retains binding activity to the target antigen (USP 4,816,567 to Cabilly et al.; Morrison et al., Proc. Natl. Acad. Sci. USA, 81: 68516855 (1984)).

[0073] As used in this application, the term "humanized antibody" refers to an antibody or antibody fragment obtained by replacing all or part of the CDR region of a human immunoglobulin (recipient antibody) with the CDR region of a non-human antibody (donor antibody), wherein the donor antibody can be a non-human (e.g., mouse, rat, or rabbit) antibody with the desired specificity, affinity, or reactivity. In addition, some amino acid residues in the framework region (FR) of the recipient antibody can also be replaced with amino acid residues of the corresponding non-human antibody, or with amino acid residues of other antibodies, to further improve or optimize the performance of the antibody. For more details on humanized antibodies, see, for example, Jones et al., Nature, 321: 522-525 (1986); Reichmann et al., Nature, 332: 323-329 (1988); Presta, Curr. Op. Struct. Biol., 2: 593-596 (1992); and Clark, Immunol. Today 21: 397-402 (2000).

[0074] As used in the present application, the term "epitope" refers to the site on an antigen that is specifically bound by an immunoglobulin or antibody. "Epitope" is also referred to as "antigenic determinant" in the art. An epitope or antigenic determinant is typically composed of chemically active surface groups of a molecule, such as amino acids or carbohydrates or sugar side chains, and typically has specific three-dimensional structural characteristics and specific charge characteristics. For example, an epitope typically comprises at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 continuous or discontinuous amino acids in a unique spatial conformation, which can be "linear" or "conformational". See, for example, Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66, G.E. Morris, Ed. (1996). In a linear epitope, all interacting points between a protein and an interacting molecule (e.g., an antibody) exist linearly along the primary amino acid sequence of the protein. In a conformational epitope, the interacting points exist across separate protein amino acid residues.

[0075] As used in this application, the term "isolated" or "isolated" means obtained from a natural state by artificial means. If a substance or component is "isolated" in nature, it may be that the natural environment in which it is located has changed, or the substance has been separated from the natural environment, or both. For example, a certain unisolated polynucleotide or polypeptide naturally exists in a living animal, and the same polynucleotide or polypeptide with high purity that is separated from this natural state is called isolated. The term "isolated" or "isolated" does not exclude the presence of artificial or synthetic substances, nor does it exclude the presence of other impure substances that do not affect the activity of the substance.

[0076] As used herein, the term "vector" refers to a nucleic acid delivery vehicle into which a polynucleotide can be inserted. When a vector is capable of expressing a protein encoded by the inserted polynucleotide, it is referred to as an expression vector. A vector can be introduced into a host cell via transformation, transduction, or transfection, allowing the genetic material it carries to be expressed in the host cell. Vectors are well known to those skilled in the art and include, but are not limited to, plasmids; phagemids; cosmids; artificial chromosomes, such as yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), or P1-derived artificial chromosomes (PACs); bacteriophages, such as lambda phage or M13 phage, and animal viruses. Animal viruses that can be used as vectors include, but are not limited to, retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpes viruses (such as herpes simplex virus), poxviruses, baculoviruses, papillomaviruses, and papillomas (such as SV40). A vector can contain a variety of elements that control expression, including, but not limited to, promoter sequences, transcription initiation sequences, enhancer sequences, selection elements, and reporter genes. In addition, a vector may also contain an initiation of replication site.

[0077] As used in this application, the term "host cell" refers to a cell that can be used to introduce a vector, including but not limited to prokaryotic cells such as Escherichia coli or Bacillus subtilis, fungal cells such as yeast cells or Aspergillus, insect cells such as S2 Drosophila cells or Sf9, or animal cells such as fibroblasts, CHO cells, COS cells, NSO cells, HeLa cells, BHK cells, HEK 293 cells or human cells.

[0078] As used herein, the term "specific binding" refers to a non-random binding reaction between two molecules, such as an antibody and its antigen. In certain embodiments, an antibody that specifically binds to an antigen (or has specificity for an antigen) means that the antibody binds to the antigen with a specificity of less than about 10 -5 M, for example, less than about 10 -6 M, 10 -7 M, 10 -8 M, 10 -9 M or 10 -10 The antibody binds to the antigen with an affinity (KD) of M or less. In some embodiments of the present application, the term "targeting" refers to specific binding.

[0079] As used in this application, the term "KD" refers to the dissociation equilibrium constant of a specific antibody-antigen interaction, which is used to describe the binding affinity between the antibody and the antigen. The smaller the equilibrium dissociation constant, the tighter the antibody-antigen binding and the higher the affinity between the antibody and the antigen. Typically, antibodies bind to antigens at a dissociation equilibrium constant of less than about 10 -5 M, for example, less than about 10 -6M, 10 -7 M, 10 -8 M, 10 -9 M or 10 -10 The antigen is bound to the antigen with a dissociation equilibrium constant (KD) of M or less, e.g., as determined using surface plasmon resonance (SPR) in a BIACORE instrument.

[0080] As used herein, the terms "monoclonal antibody" and "monoclonal antibody" have the same meaning and are used interchangeably; the terms "polyclonal antibody" and "polyclonal antibody" have the same meaning and are used interchangeably; the terms "polypeptide" and "protein" have the same meaning and are used interchangeably. Furthermore, in this application, amino acids are generally represented by single-letter and three-letter abbreviations known in the art. For example, alanine can be represented by A or Ala.

[0081] As used herein, the term "pharmaceutically acceptable excipient" refers to a carrier and / or excipient that is pharmacologically and / or physiologically compatible with the subject and the active ingredient, which is well known in the art (see, for example, Remington's Pharmaceutical Sciences. Edited by Gennaro AR, 19th ed. Pennsylvania: Mack Publishing Company, 1995), and includes, but is not limited to, pH adjusters, surfactants, adjuvants, and ionic strength enhancers. For example, pH adjusters include, but are not limited to, phosphate buffers; surfactants include, but are not limited to, cationic, anionic, or nonionic surfactants, such as Tween-80; and ionic strength enhancers include, but are not limited to, sodium chloride.

[0082] As used in this application, the term "adjuvant" refers to a nonspecific immunopotentiator that, when delivered together with an antigen or in advance into the body, can enhance the body's immune response to the antigen or change the type of immune response. There are many types of adjuvants, including but not limited to aluminum adjuvants (such as aluminum hydroxide), Freund's adjuvants (such as complete Freund's adjuvant and incomplete Freund's adjuvant), Corynebacterium brevis, lipopolysaccharide, cytokines, etc. Freund's adjuvant is the most commonly used adjuvant in current animal experiments. Aluminum hydroxide adjuvant is more commonly used in clinical trials.

[0083] As used in this application, the term "effective amount" refers to an amount sufficient to obtain or at least partially obtain the desired effect. For example, an effective amount for preventing a disease (e.g., a disease related to the binding of PD-1 to PD-L1 or excessive expression of VEGF, such as a tumor) refers to an amount sufficient to prevent, stop, or delay the occurrence of a disease (e.g., a disease related to the binding of PD-1 to PD-L1 or excessive expression of VEGF, such as a tumor); an effective amount for treating a disease refers to an amount sufficient to cure or at least partially prevent the disease and its complications in a patient already suffering from the disease. Determining such an effective amount is entirely within the capabilities of those skilled in the art. For example, an amount effective for therapeutic use will depend on the severity of the disease to be treated, the overall state of the patient's own immune system, the patient's general condition, such as age, weight and sex, the mode of administration of the drug, and other treatments administered simultaneously.

[0084] After in-depth research and creative work, the inventors of the present application have obtained a humanized bispecific antibody that can simultaneously bind to VEGF and PD-1, and can simultaneously block the binding of VEGFA to VEGFR2, and block the binding of PD-1 to PD-L1.

[0085] The inventors of the present application have discovered that the bispecific antibody described in the present application not only has good thermal stability and long-term stability, but also can: effectively bind to PD-1 on the surface of human immune cells, relieve immunosuppression mediated by PD-L1 and PD-1, effectively activate the activity of T cells, and promote the secretion of cytokines IFN-γ and IL-2 by human immune cells; can specifically bind to the VEGF antigen, block the binding of VEGFA to its receptor, and then block the downstream signaling pathway, effectively inhibiting VEGFA-induced proliferation of vascular endothelial cells, thereby inhibiting tumor-induced angiogenesis; can effectively inhibit VEGF-induced HUVEC cell proliferation, and can be used to prepare drugs for the prevention and treatment of malignant tumors, inhibiting the development and deterioration of cancer.

[0086] Malignant tumors as described in this application are also referred to as cancers.

[0087] In the first aspect of the present application, a bispecific antibody is provided, comprising a first protein functional region and a second protein functional region; wherein: the first protein functional region is an anti-PD-1 antibody or an antigen-binding fragment thereof, and the second protein functional region is an anti-VEGF antibody or an antigen-binding fragment thereof, and the anti-VEGF antibody or antigen-binding fragment thereof comprises a heavy chain variable region, and the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 whose amino acid sequences are shown in SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9, respectively.

[0088] In some embodiments of the present application, the anti-PD-1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region and / or a light chain variable region; the amino acid sequences of HCDR1, HCDR2 and HCDR3 contained in the heavy chain variable region are respectively selected from the amino acid sequences of HCDR1, HCDR2 and HCDR3 contained in the heavy chain variable region of nivolumab, pembrolizumab, cemipril limab, toripalimab, sintilimab or carrelizumab; the amino acid sequences of LCDR1, LCDR2 and LCDR3 contained in the light chain variable region are respectively selected from the amino acid sequences of LCDR1, LCDR2 and LCDR3 contained in the light chain variable region of nivolumab, pembrolizumab, cemipril limab, toripalimab, sintilimab or carrelizumab.

[0089] In some embodiments of the present application, the anti-PD-1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region and / or a light chain variable region, wherein the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 as shown in amino acid sequences of SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, respectively, and the light chain variable region comprises LCDR1, LCDR2 and LCDR3 as shown in amino acid sequences of SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6, respectively.

[0090] In some embodiments of the present application, the anti-PD-1 antibody or antigen-binding fragment thereof comprises: a heavy chain variable region having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence of SEQ ID NO: 10, and a light chain variable region having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence of SEQ ID NO: 11; and / or

[0091] The anti-VEGF antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence shown in SEQ ID NO: 12.

[0092] The variable regions of the light and heavy chains determine antigen binding; each chain's variable region contains three hypervariable regions, called complementarity-determining regions (CDRs). The heavy (H) chain CDRs consist of HCDR1, HCDR2, and HCDR3, while the light (L) chain CDRs consist of LCDR1, LCDR2, and LCDR3. These are named by Kabat et al. (Sequences of Proteins of Immunological Interest, Fifth Edition (1991), Vols. 1-3, NIH Publication 91-3242, Bethesda, MD).

[0093] Methods and techniques for identifying CDRs in the amino acid sequences of heavy and light chain variable regions are known in the art and can be used to identify CDRs in the amino acid sequences of specific heavy and / or light chain variable regions disclosed herein. Exemplary well-known techniques that can be used to identify CDR boundaries include, for example, the Kabat definition method, the Chothia definition method, and the AbM definition method. See, for example, Kabat, Sequences of Proteins of Immunological Interest, National Institutes of Health, Bethesda, Md. (1991); Al-Lazikani et al., Standard conformations for the canonical structures of immunoglobulins., J. Mol. Biol. 273:927-948 (1997); and Martin AC et al., Modeling antibody hypervariable loops: a combined algorithm, Proc. Natl. Acad. Sci. USA 86:9268-9272 (1989).

[0094] The amino acid sequence of the CDR region of the bispecific antibody described in this application was obtained using techniques well known to those skilled in the art (KABAT scheme). The specific sequence is as follows:

[0095] Anti-PD-1 antibodies or their antigen-binding fragments contain three heavy chain complementarity determining regions:

[0096] PD-1-HCDR1:DYEMH (SEQ ID NO: 1);

[0097] PD-1-HCDR2: VIESETGGTAYNQKFKG (SEQ ID NO: 2);

[0098] PD-1-HCDR3: EGITTVATTYYWYFDV (SEQ ID NO: 3).

[0099] Anti-PD-1 antibodies or their antigen-binding fragments contain three light chain complementarity determining regions:

[0100] PD-1-LCDR1: RSSQSIVHSNGNTYLE (SEQ ID NO: 4);

[0101] PD-1-LCDR2: KVSNRFS (SEQ ID NO: 5);

[0102] PD-1-LCDR3: FQGSHVPLT (SEQ ID NO: 6).

[0103] The anti-VEGF antibody or antigen-binding fragment thereof comprises three heavy chain complementarity determining regions:

[0104] VEGF-HCDR1: ATDID (SEQ ID NO: 7);

[0105] VEGF-HCDR2: RIFSPSDFTDYADSVKG (SEQ ID NO: 8);

[0106] VEGF-HCDR3: PDTYAYNIFLDTPTYNALHY (SEQ ID NO: 9).

[0107] In some embodiments of the present application, the bispecific antibody, wherein,

[0108] The anti-PD-1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region with an amino acid sequence as shown in SEQ ID NO: 10 and a light chain variable region with an amino acid sequence as shown in SEQ ID NO: 11; and / or

[0109] The anti-VEGF antibody or antigen-binding fragment thereof comprises a heavy chain variable region with an amino acid sequence as shown in SEQ ID NO: 12.

[0110] The heavy chain variable region (VH) of an anti-PD-1 antibody or antigen-binding fragment thereof, wherein the bold underlined portion represents the CDR:

[0111] PD-1-VH:

[0112] The light chain variable region (VL) of an anti-PD-1 antibody or antigen-binding fragment thereof, wherein the bold underlined portion represents the CDR:

[0113] PD-1-VL:

[0114] The anti-VEGF antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VH), wherein the bold underlined portion represents the CDR:

[0115] VEGF-VH:

[0116] In some embodiments of the present application, the anti-PD-1 antibody or its antigen-binding fragment is selected from Fab, Fab', F(ab')2, Fd, Fv, dAb, complementarity determining region fragment, single domain antibody, single chain antibody, humanized antibody, chimeric antibody or diabody; and / or, the anti-VEGF antibody or its antigen-binding fragment is selected from Fab, Fab', F(ab')2, Fd, Fv, dAb, complementarity determining region fragment, single domain antibody, single chain antibody, humanized antibody, chimeric antibody or diabody.

[0117] In some embodiments of the present application, the first protein functional region is an immunoglobulin, whose heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, respectively, and its light chain variable region comprises LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6, respectively; and / or, the second protein functional region is a single domain antibody, whose heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9, respectively.

[0118] In some embodiments of the present application, the first protein functional region is an immunoglobulin, and the immunoglobulin is selected from IgG, IgA, IgD, IgE or IgM; preferably IgG.

[0119] In some embodiments of the present application, the first protein functional region is an immunoglobulin, which includes a non-CDR region, and the non-CDR region is from a species other than a mouse, such as a human antibody.

[0120] In some embodiments of the present application, the first protein functional region is an immunoglobulin, and the constant region of the immunoglobulin is derived from a human antibody; preferably, the constant region of the immunoglobulin is selected from the constant region of human IgG1, IgG2, IgG3 or IgG4.

[0121] In some embodiments of the present application, the first protein functional region is an immunoglobulin, and the second protein functional region is a single domain antibody; there are two single domain antibodies, and one end of each of the single domain antibodies is respectively connected to the C-terminus or N-terminus of the two heavy chains of the immunoglobulin; or one end of each of the single domain antibodies is respectively connected to the C-terminus or N-terminus of the two light chains of the immunoglobulin; or the N-terminus of each of the single domain antibodies is respectively connected to the C-terminus of the heavy chain constant region CH1 of the immunoglobulin, and the C-terminus of each of the single domain antibodies is respectively connected to the N-terminus of the heavy chain constant region CH2 of the immunoglobulin.

[0122] In some embodiments of the present application, the bispecific antibody is selected from the following forms:

[0123] (1) The first polypeptide chain of the bispecific antibody is represented by the formula VLPD-1-CL, and the second polypeptide chain is represented by the formula VHVEGF-linker-VHPD-1-CH1-hinge-CH2-CH3; or

[0124] (2) The first polypeptide chain of the bispecific antibody is represented by the formula VLPD-1-CL, and the second polypeptide chain is represented by the formula VHPD-1-CH1-hinge-CH2-CH3-linker-VHVEGF; or

[0125] (3) The first polypeptide chain of the bispecific antibody is represented by the formula VLPD-1-CL, and the second polypeptide chain is represented by the formula VHPD-1-CH1-Linker-VHVEGF-Linker-Hinge-CH2-CH3; or

[0126] (4) The first polypeptide chain of the bispecific antibody is represented by the formula VHVEGF-linker-VLPD-1-CL, and the second polypeptide chain is represented by the formula VHPD-1-CH1-hinge-CH2-CH3.

[0127] The VLPD-1 described in this application refers to the VL of an anti-PD-1 antibody or an antigen-binding fragment thereof, VHPD-1 refers to the VH of an anti-PD-1 antibody or an antigen-binding fragment thereof; and VHVEGF refers to the VH of an anti-VEGF antibody or an antigen-binding fragment thereof.

[0128] The present application has no particular limitation on the amino acid sequence of the linker, as long as the purpose of the invention of the present application can be achieved. For example, the amino acid sequence of the linker can be (GGGGS)n, where n is selected from 1, 2, 3, 4 or 5, preferably 1, 2 or 3. The present application has no particular limitation on the amino acid sequence of the hinge, as long as the purpose of the invention of the present application can be achieved.

[0129] In some embodiments of the present application, the bispecific antibody is selected from the following:

[0130] (1) the first polypeptide chain comprises the amino acid sequence shown in SEQ ID NO: 13, and the second polypeptide chain comprises the amino acid sequence shown in SEQ ID NO: 14; or

[0131] (2) the first polypeptide chain comprises the amino acid sequence shown in SEQ ID NO: 13, and the second polypeptide chain comprises the amino acid sequence shown in SEQ ID NO: 15; or

[0132] (3) the first polypeptide chain comprises the amino acid sequence shown in SEQ ID NO: 13, and the second polypeptide chain comprises the amino acid sequence shown in SEQ ID NO: 16; or

[0133] (4) The first polypeptide chain comprises the amino acid sequence shown in SEQ ID NO: 17, and the second polypeptide chain comprises the amino acid sequence shown in SEQ ID NO: 18.

[0134] The second aspect of the present application provides an isolated nucleic acid molecule encoding the bispecific antibody described in the first aspect of the present application.

[0135] The third aspect of the present application provides a vector comprising the isolated nucleic acid molecule described in the second aspect of the present application.

[0136] The fourth aspect of the present application provides a host cell comprising the isolated nucleic acid molecule described in the second aspect of the present application, or comprising the vector described in the third aspect of the present application.

[0137] The fifth aspect of the present application provides a method for preparing the bispecific antibody described in the first aspect of the present application, which comprises culturing the host cell described in the fourth aspect of the present application under suitable conditions, and recovering the bispecific antibody from the cell culture.

[0138] A sixth aspect of the present application provides a conjugate comprising the bispecific antibody described in the first aspect of the present application and a conjugated moiety, wherein the conjugated moiety is a therapeutically active substance or a detectable label. In some embodiments, the conjugated moiety is selected from a toxin (such as a cytotoxin), a cytokine, or a radionuclide; in some embodiments, the conjugated moiety is selected from a topoisomerase I inhibitor, camptothecin, and derivatives. In some embodiments, the conjugated moiety is selected from a radioisotope, a fluorescent substance, a luminescent substance, a colored substance, or an enzyme.

[0139] The seventh aspect of the present application provides a kit comprising the bispecific antibody described in the first aspect of the present application, or the conjugate described in the sixth aspect of the present application.

[0140] Preferably, the kit further comprises a second antibody capable of specifically binding to the bispecific antibody; optionally, the second antibody further comprises a detectable label, such as a radioisotope, a fluorescent substance, a luminescent substance, a colored substance or an enzyme.

[0141] The eighth aspect of the present application provides use of the bispecific antibody described in the first aspect of the present application in preparing a kit; preferably, the kit is used to detect the presence or level of VEGF and / or PD-1 in a sample.

[0142] The ninth aspect of the present application provides a pharmaceutical composition, which comprises the bispecific antibody described in the first aspect of the present application or the conjugate described in the sixth aspect of the present application; optionally, it also includes a pharmaceutically acceptable excipient.

[0143] The bispecific antibodies provided in the first aspect of the present application or the pharmaceutical compositions provided in the ninth aspect of the present application can be formulated into any dosage form known in the pharmaceutical art, for example, tablets, pills, suspensions, emulsions, solutions, gels, capsules, powders, granules, elixirs, lozenges, suppositories, injections (including injections, sterile powders for injection and concentrated solutions for injection), inhalants, sprays, etc. The preferred dosage form depends on the intended route of administration and therapeutic use. The pharmaceutical compositions of the present application should be sterile and stable under the conditions of production and storage, and the preferred dosage form is an injection. Such injections can be sterile injectable solutions. For example, sterile injectable solutions can be prepared by the following method: the necessary dose of the bispecific antibodies of the present application is incorporated into an appropriate solvent, and optionally, other desired ingredients (including but not limited to pH adjusters, surfactants, adjuvants, ionic strength enhancers, isotonic agents, preservatives, diluents, or any combination thereof) are simultaneously incorporated, followed by filtration sterilization. In addition, sterile injectable solutions can be prepared as sterile lyophilized powders (for example, by vacuum drying or freeze drying) for ease of storage and use. Such sterile lyophilized powders can be dispersed in a suitable vehicle, such as water for injection, before use.

[0144] In addition, the bispecific antibody of the present application can be present in pharmaceutical composition with unit dosage form, so that it is easy to use.In certain embodiments, the unit dosage is at least 1mg, at least 5mg, at least 10mg, at least 15mg, at least 25mg, at least 30mg, at least 45mg, at least 50mg, at least 75mg, or at least 100mg.In the case where the pharmaceutical composition is liquid (such as injection) dosage form, it can comprise concentration and be at least 0.1mg / mL, such as at least 0.25mg / mL, at least 0.5mg / mL, at least 1mg / mL, at least 2.5mg / mL, at least 5mg / mL, at least 8mg / mL, at least 10mg / mL, at least 15mg / mL, at least 25mg / mL, at least 50mg / mL, at least 75mg / mL, or at least 100mg / mL of the bispecific antibody of the present application.

[0145] The bispecific antibody of the present application or pharmaceutical composition can be used by any suitable method known in the art, including but not limited to oral, oral, sublingual, eyeball, local, parenteral, rectal, intrathecal, intracytoplasmic reticulum groove, groin, intravesical, local (such as, powder, ointment or drops), or nasal route. However, for many therapeutic uses, preferred route of administration / mode is parenteral administration (such as intravenous injection, subcutaneous injection, intraperitoneal injection, intramuscular injection). Technicians should understand that route of administration and / or mode will change according to the intended purpose. In a preferred embodiment, the bispecific antibody of the present application or pharmaceutical composition are given by intravenous infusion or injection.

[0146] The bispecific antibodies or pharmaceutical compositions provided herein can be used alone or in combination, or in combination with another pharmaceutically active agent (e.g., a tumor chemotherapy drug). Such another pharmaceutically active agent can be administered before, simultaneously with, or after the administration of the bispecific antibodies or pharmaceutical compositions of the present application.

[0147] In the present application, the dosage regimen can be adjusted to obtain the best intended response (e.g., therapeutic or preventive response). For example, a single dose can be administered, multiple doses can be administered over a period of time, or the dosage can be proportionally reduced or increased according to the urgency of the treatment situation.

[0148] In the prior art, the combination of anti-angiogenic therapy and immune checkpoint inhibitors has shown good efficacy in many tumors. The combination of anti-VEGF antibodies, such as Bevacizumab, and anti-PD-1 / PD-L1 antibodies, such as Nivolumab, Pembrolizumab, and Atezolizumab, has shown good efficacy in ovarian cancer (Joyce F. Liu et al., JAMA Oncol. 2019; 5(12): 1731-1738.), non-small cell lung cancer (including non-small cell lung cancer with EGFR and / or ALK sensitive mutations) (Manegold C, et al., J Thorac Oncol. 2017 Feb; 12(2): 194-207.), renal cell carcinoma (Dudek AZ et al., J Clin Oncol. 2018; 36(suppl; abstr 4558.), hepatocellular carcinoma (Stein S et al., J Clin Oncol, 2018, 36(15_suppl):4074.; In 2020, the FDA approved bevacizumab combined with atezolizumab for the treatment of hepatocellular carcinoma), colorectal cancer (including MSI-H / dMMR and non-MSI-H / dMMR types) (Bendell JC et al. American Society of Clinical Oncology; May 29-June 2, 2015; Chicago, IL. 2015; abstract 704; Hochster HS et al. American Society of Clinical Oncology Gastrointestinal Cancers Symposium; January 19-21, 2017; San Francisco, CA. 2017; abstract 673.), and breast cancer (Yukinori Ozaki et al., AACR; Cancer Res 2020; 80(4Suppl):Abstract nr PD1-03.); The combination of PD-1 antibody (Pembrolizumab) and angiogenesis inhibitor (Lenvatinib) has shown good efficacy in the treatment of endometrial cancer and was approved by the FDA in 2019 for the treatment of endometrial cancer.

[0149] The results of a recently published clinical trial showed that the PD-1 / VEGF bispecific antibody ivonescimab (AK112) showed preliminary efficacy in solid tumors (most of the patients included had tumor types previously considered to be unresponsive to single-agent immunotherapy, such as ovarian serous carcinoma, MSS colorectal cancer, and other cancers), with an ORR of 25.5% and a disease control rate (DCR) of 63.8% (J Immunother Cancer. 2024; 12(4): e008037.). The prior art also disclosed that ivonescimab combined with chemotherapy has excellent efficacy in treating patients with locally advanced or metastatic nsq-NSCLC who have progressed after EGFR-TKI treatment.

[0150] The PD-1 antibody toripalimab has been approved for the treatment of melanoma, nasopharyngeal carcinoma, urothelial carcinoma, esophageal squamous cell carcinoma, and non-small cell lung cancer.

[0151] Existing studies have also found that VEGF is closely related to tumor immunity (Immunity. 2013, 39(1): 61-73. Cancer Metastasis Rev, 2011, 30(1): 83-95.). In the tumor microenvironment, upregulated VEGF can act on endothelial cells, inhibiting the expression of adhesion molecules, thereby inhibiting the adhesion and infiltration of T cells; VEGF can also upregulate the expression of multiple immunosuppressive molecules such as PD-L1, PD-L1, TIM-3, IDO, etc., inhibiting the activation of effector T cells. Simultaneously inhibiting PD-1 signaling and VEGF signaling will have a better anti-tumor effect. Animal experimental data and clinical data reported in the literature initially support this strategy (Clin Exp Immunol, 2013, 172(3): 500-6. Sznol et al, ASCO, GU 2015). The combination of PD-1 monoclonal antibody and VEGFR2 monoclonal antibody, and the combination of PD-L1 monoclonal antibody and VEGF monoclonal antibody have shown good synergistic effects. Combining bevacizumab, a monoclonal antibody targeting VEGF, with chemotherapy can significantly improve the survival of patients with colorectal cancer (Hurwitz et al. New Eng J Med 2004;350:2335-2342) or advanced non-squamous NSCLC (Sandler et al. J Clin Oncol 2005 23(16s pt 1):2ss).

[0152] Therefore, the tenth aspect of the present application provides the use of the bispecific antibody described in the first aspect of the present application, the conjugate described in the sixth aspect of the present application, or the pharmaceutical composition described in the ninth aspect of the present application in the preparation of a drug for preventing and / or treating a malignant tumor, or at least plays a role in a drug that inhibits the development and worsening of a malignant tumor. The malignant tumor is a tumor that overexpresses PD-L1 protein (i.e., PD-L1 positive) and / or overexpresses VEGF protein (i.e., VEGF positive). For example, the malignant tumor is a solid tumor. At least, the bispecific antibody of the present application can treat and / or inhibit the development and worsening of lung cancer, colon cancer, colorectal cancer (CRC), melanoma or ovarian cancer. Preferably, the lung cancer is non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC). More preferably, the non-small cell lung cancer is squamous non-small cell lung cancer or non-squamous non-small cell lung cancer (nsq-NSCLC). More preferably, the non-squamous non-small cell lung cancer is locally advanced or metastatic nsq-NSCLC.

[0153] In the eleventh aspect of the present application, a method for treating or ameliorating a malignant tumor is provided, comprising administering the bispecific antibody described in the first aspect of the present application, the conjugate described in the sixth aspect of the present application, or the pharmaceutical composition described in the ninth aspect of the present application to a patient in need thereof; wherein the malignant tumor is a tumor overexpressing PD-L1 and / or VEGF; preferably, the malignant tumor is a solid tumor; more preferably, the malignant tumor is lung cancer, colon cancer, colorectal cancer (CRC), melanoma, or ovarian cancer; more preferably, the lung cancer is non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC); more preferably, the non-small cell lung cancer is squamous non-small cell lung cancer or non-squamous non-small cell lung cancer (nsq-NSCLC); more preferably, the non-squamous non-small cell lung cancer is locally advanced or metastatic nsq-NSCLC.

[0154] The twelfth aspect of the present application provides a method for regulating immune response and regulating tumor angiogenesis, which comprises administering the bispecific antibody described in the first aspect of the present application, or the conjugate described in the sixth aspect of the present application, or the pharmaceutical composition described in the ninth aspect of the present application to a patient in need; preferably, the regulating immune response is achieved by blocking the binding of PD-1 to its receptor, and the regulating tumor angiogenesis is achieved by blocking the binding of VEGF to its receptor.

[0155] The thirteenth aspect of the present application provides the use of the bispecific antibody described in the first aspect of the present application, the conjugate described in the sixth aspect of the present application, or the pharmaceutical composition described in the ninth aspect of the present application in the preparation of the following drugs or reagents: a reagent for detecting the VEGF level in a sample.

[0156] In a fourteenth aspect, the present application provides use of the bispecific antibody described in the first aspect of the present application, the conjugate described in the sixth aspect of the present application, or the pharmaceutical composition described in the ninth aspect of the present application in the preparation of the following drugs or reagents:

[0157] (1) a drug or agent that detects the level of VEGFA in a sample, or a drug or agent that blocks the binding of VEGFA to VEGFR2, or a drug or agent that downregulates the activity or level of VEGFA, or a drug or agent that relieves the stimulatory effect of VEGFA on vascular endothelial cell proliferation, or a drug or agent that inhibits vascular endothelial cell proliferation, or a drug or agent that blocks tumor angiogenesis; and / or

[0158] (2) Drugs or agents that block the binding of PD-1 to PD-L1, or drugs or agents that downregulate the activity or level of PD-1, or drugs or agents that relieve the immune suppression of the body by PD-1, or drugs or agents that promote the secretion of IFN-γ in T lymphocytes, or drugs or agents that promote the secretion of IL-2 in T lymphocytes.

[0159] In some embodiments of the present application, the use is for non-therapeutic and / or non-diagnostic purposes.

[0160] A fifteenth aspect of the present application provides an in vivo or in vitro method, comprising the step of administering to cells an effective amount of the bispecific antibody of the first aspect of the present application, the conjugate of the sixth aspect of the present application, or the pharmaceutical composition of the ninth aspect of the present application, wherein the method is selected from the following:

[0161] (1) a method for detecting the level of VEGFA in a sample, or a method for blocking the binding of VEGFA to VEGFR2, or a method for downregulating the activity or level of VEGFA, or a method for relieving the stimulatory effect of VEGFA on vascular endothelial cell proliferation, or a method for inhibiting vascular endothelial cell proliferation, or a method for blocking tumor angiogenesis; and / or

[0162] (2) Methods for blocking the binding of PD-1 to PD-L1, or methods for downregulating the activity or level of PD-1, or methods for relieving the immune suppression of the body by PD-1, or methods for promoting the secretion of IFN-γ in T lymphocytes, or methods for promoting the secretion of IL-2 in T lymphocytes.

[0163] In some embodiments of the present application, the in vitro method is for non-therapeutic and / or non-diagnostic purposes.

[0164] In the in vitro experiments of the present application, the anti-VEGF-anti-PD-1 bispecific antibodies can specifically bind to the VEGF antigen, thereby inhibiting the proliferation of HUVEC cells; and the anti-VEGFA-anti-PD-1 bispecific antibodies can promote the secretion of IFN-γ and / or IL-2, thereby activating the immune response.

[0165] The sixteenth aspect of the present application provides a method for preventing and / or treating malignant tumors, comprising the step of administering to a subject an effective amount of the bispecific antibody described in the first aspect of the present application, or the conjugate described in the sixth aspect of the present application, or the pharmaceutical composition described in the ninth aspect of the present application.

[0166] The typical non-limiting range of a therapeutically or prophylactically effective amount of the bispecific antibody of the present application is 0.02-50 mg / kg. It should be noted that the dosage may vary depending on the type and severity of the symptoms to be treated. In addition, those skilled in the art understand that for any particular patient, the specific dosing regimen should be adjusted over time based on the patient's needs and the doctor's professional evaluation; the dosage range given here is for illustrative purposes only and does not limit the use or scope of the pharmaceutical composition of the present application.

[0167] In the present application, the subject may be a mammal, preferably a primate, including rhesus monkeys, cynomolgus monkeys or humans.

[0168] In the seventeenth aspect, the present application provides a bispecific antibody as described in the first aspect of the present application, or the conjugate as described in the sixth aspect of the present application, or the pharmaceutical composition as described in the ninth aspect of the present application, which is used for preventing and / or treating malignant tumors.

[0169] In an eighteenth aspect, the present application provides a bispecific antibody according to the first aspect of the present application, or the conjugate according to the sixth aspect of the present application, or the pharmaceutical composition according to the ninth aspect of the present application, for use in:

[0170] (1) detecting the level of VEGFA in a sample, or blocking the binding of VEGFA to VEGFR2, or downregulating the activity or level of VEGFA, or relieving the stimulatory effect of VEGFA on vascular endothelial cell proliferation, or inhibiting vascular endothelial cell proliferation, or blocking tumor angiogenesis; and / or

[0171] (2) Block the binding of PD-1 to PD-L1, or downregulate the activity or level of PD-1, or relieve the immune suppression of the body by PD-1, or promote the secretion of IFN-γ in T lymphocytes, or promote the secretion of IL-2 in T lymphocytes.

[0172] The present application will be further described below with reference to specific examples. It should be understood that these examples are intended to illustrate the present application only and are not intended to limit the scope of the present application. All reagents used in the experiments, unless otherwise specified, are commercially available. Furthermore, unless otherwise specified, "parts" and "%" are by mass, "room temperature" is 20-30°C, and "overnight" means 12-16 hours.

[0173] Example 1. Preparation of bispecific antibody molecules

[0174] 1. Construction of bispecific antibody expression vector

[0175] (1) Construction of an anti-PD-1 antibody expression vector

[0176] First expression vector corresponding to the light chain of the anti-PD-1 antibody: A DNA sequence encoding 3E4L1 (specific sequence shown in SEQ ID NO: 21) was synthesized, digested with BSPQI, and ligated into the HXT2 vector (appropriately modified based on the pCDNA3.1 vector, specific sequence shown in SEQ ID NO: 22) to obtain the expression vector HXT2-3E4L1;

[0177] The second expression vector corresponding to the heavy chain of the anti-PD-1 antibody (i.e., JS001 HC): The DNA sequence encoding 1A6H2-QGQ (the specific sequence is shown in SEQ ID NO: 23) was synthesized, digested by BSPQI and ligated to the HXT4S vector (appropriately modified based on the pCDNA3.1 vector, the specific sequence is shown in SEQ ID NO: 24) to obtain the expression vector HXT4S-1A6H2-QGQ.

[0178] (2) Construction of an expression vector for anti-VEGF single-domain antibody

[0179] A DNA sequence encoding IgG4-FC was synthesized (specific sequence shown in SEQ ID NO: 25), digested with BSPQI-NotI enzymes, and ligated into the HXT4S vector to generate the expression vector HX4-FC.

[0180] A DNA sequence encoding 16C2-1 (specific sequence shown in SEQ ID NO: 26) was synthesized and inserted into the HX4-FC vector (specific sequence shown in SEQ ID NO: 27) via the SapI-SapI site to obtain the expression vector HX4-16C2-1Fc.

[0181] (3) Construction of bispecific antibody molecule expression vector

[0182] 1) Bispecific antibody molecule 23:

[0183] The construction method of the first expression vector HXT2-3E4L1 is the same as the construction method of the first expression vector in “(1) Construction of an expression vector for an anti-PD-1 antibody”;

[0184] A DNA sequence encoding 16C2-1-JS001 HC (specific sequence shown in SEQ ID NO: 28) was synthesized, digested with EcoRI-NheI and ligated into the HXT4S vector to obtain the second expression vector HXT4S-16C2-1-JS001 HC.

[0185] 2) Bispecific antibody molecule 24:

[0186] The construction method of the first expression vector HXT2-3E4L1 is the same as the construction method of the first expression vector in “(1) Construction of an expression vector for an anti-PD-1 antibody”;

[0187] A DNA sequence encoding IgG4-16C2-1 (the specific sequence is shown in SEQ ID NO: 29) was synthesized, digested with NheI-NotI enzymes, and ligated into the HXT4S-1A6H2-QGQ vector (i.e., the second expression vector corresponding to the heavy chain of the anti-PD-1 antibody) to obtain the second expression vector HXT4s-JS001 HC-16C2-1.

[0188] 3) Bispecific antibody molecule 27:

[0189] The construction method of the first expression vector HXT2-3E4L1 is the same as the construction method of the first expression vector in “(1) Construction of an expression vector for an anti-PD-1 antibody”;

[0190] The DNA sequence encoding JS001 HC-CH1-16C2-1 (specific sequence shown in SEQ ID NO: 30) was synthesized, digested with SapI-SapI enzymes and ligated into the HX4-FC vector to obtain the second expression vector HXT4S-JS001 HC-CH1-16C2-1-FC.

[0191] 4) Bispecific antibody molecule 28:

[0192] A DNA sequence encoding 16C2-1-3E4L1 (specific sequence shown in SEQ ID NO: 34) was synthesized, digested with SapI-SapI enzymes, and ligated into the HXT2 vector to obtain the first expression vector HXT2-16C2-1-3E4L1;

[0193] The construction method of the second expression vector HXT4S-1A6H2-QGQ is the same as the construction method of the second expression vector in “1. Second expression vector corresponding to the heavy chain of the anti-PD-1 antibody”.

[0194] 2. Expression of bispecific antibody molecules

[0195] Count the CHO-K1 cells in culture. When the cell density is 2×10 6 / mL-6×10 6 / mL, and then subculture and expand using CD CHO medium (Thermofisher, 12490-003). The day before transfection, the cell density was diluted to 1.5×10 6 / mL-2.0×10 6 / mL, the next day when the cell density reached about 3.0×10 6 / mL-4.0×10 6 First, add one-tenth of the transfection volume of CD CHO culture medium, then add 1-2 μg / mL of the plasmid (prepared in "1. Construction of bispecific antibody molecule expression vector" above), and finally add 3-14 μg / mL of PEI (polyethyleneimine, Polysciences, 24765-1). After mixing, incubate at room temperature for no more than 30 minutes. Finally, slowly add the transfection mixture to the treated cells at a density of about 3.0×10 6 / mL-4.0×10 6 Add 400 mL of CHO-K1 cells and mix thoroughly. Incubate the transfected mixture in a CO2 shaker at 36.5°C, 110 rpm, and 7% (volume fraction) CO2. Feed the cells with 4 vol% Cell Boost 7a (Hyclone, SH31026.05) and 0.4 vol% Cell Boost 7b (Hyclone, SH31027.04CN) on the first day after transfection. Feed the cells every two days thereafter. Harvest samples 5-9 days after transfection.

[0196] 3. Purification of bispecific antibody molecules

[0197] After the incubation period, the cells were centrifuged at 1000 g for 5 min, the precipitate discarded, and then centrifuged at 12000 g for 30 min. The cell supernatant was collected and sterile filtered using a 0.22 μm filter cup. Purification was performed using an AKTA Avant purifier. A mabselect sure LX column (Cytiva, 17547405) was first subjected to CIP with 0.1 M NaOH for 15-20 min. The column was then equilibrated with PBS buffer until all curves became horizontal before loading the sample. After loading, the column was washed with affinity chromatography wash buffer, and the target protein was eluted with acetic acid-sodium acetate buffer at pH 3.6. The sample was neutralized with 1 M Tris buffer, the pH adjusted to 5.5, and a sample was sent for SEC-HPLC (size exclusion high performance liquid chromatography) to test the sample purity. The remaining samples were purified in the next step; Eshmuno CPX (Merck, 1200830100) was used for purification, the equilibrium solution was a pH 5.5 50mM acetic acid-sodium acetate system, the eluent was a pH 5.5 50mM acetic acid-sodium acetate + 1M NaCl buffer system, and a linear elution method was used to collect the target protein. The final SEC-HPLC monomer purity reached more than 95%.

[0198] The structure of the prepared bispecific antibody molecule, antibody 23, is shown in Figure 2a, the structure of antibody 24 is shown in Figure 2b, the structure of antibody 27 is shown in Figure 2c, and the structure of antibody 28 is shown in Figure 2d. The amino acid sequences contained in the bispecific antibody molecules are shown in Table 1 below. The DotAb in Figures 2a to 2d is a single domain antibody (VHH) that specifically binds to VEGF (anti-VEGF), and has the VHH sequence shown in SEQ ID NO: 12.

[0199] Table 1 Amino acid sequences contained in bispecific antibody molecules

[0200] Example 2: Stability of bispecific antibodies

[0201] 1. Thermal stability of bispecific antibodies

[0202] DSF (differential scanning fluorescence) was used to investigate the stability of the bispecific antibody in a buffer system (20 mM histidine-histidine hydrochloride buffer, 230 mM sucrose, prepared in ultrapure water, pH 5.0).

[0203] The bispecific antibody samples were replaced in the aforementioned buffer system, with the sample concentration controlled at approximately 10 mg / mL, and assayed using nanoDSF (micro-differential scanning fluorescence). The results are shown in Table 2. The thermal transition temperatures (Tm) of the bispecific antibodies 23, 24, and 27 provided herein were all above 56°C, demonstrating good thermal stability.

[0204] Table 2 Thermal stability of bispecific antibodies

[0205] Note: “ / ” represents non-existence.

[0206] 2. Long-term stability of bispecific antibodies

[0207] Bispecific antibody samples were exchanged into a pH 5.0 buffer system (20 mM histidine-histidine hydrochloride buffer, 230 mM sucrose). The bispecific antibody concentration was controlled at approximately 10 mg / mL and aliquoted into vials at 500 μL per vial. The vials were then stored in a 5°C medical refrigerator and stability was assessed at 0, 2, and 4 weeks. Stability was assessed using the following parameters: (a) Size-exclusion high-performance liquid chromatography (SEC-HPLC) was used to measure the content of monomers, aggregates, and fragments; (b) Sodium dodecyl sulfate capillary electrophoresis (CE-SDS) was used to determine the molecular weight of the antibody; (c) The isoelectric point (IP) of each component was determined using a capillary electrophoresis instrument equipped with an icIEF cartridge (Maurice Instruments); the sample was diluted with the iCIEF mixture and then analyzed using a capillary electrophoresis instrument (Maurice Instruments); components with different isoelectric points were focused at different locations, achieving focusing and separation; and (d) Antibody biological activity was assessed using ELISA and reporter gene assays.

[0208] Wherein, (a) SEC-HPLC (size exclusion high performance liquid chromatography) measurement of the content of antibody monomers, polymers and fragments comprises the following steps: using a SEC column (Waters XBridge BEH, 7.8 mm × 30 cm, 3.5 μm, SEC purity was determined using an HPLC (Waters e2695 instrument) with a flow cytometer. Each sample was diluted to 4.0 mg / mL with mobile phase, mixed thoroughly, added to the inner liner, and directly injected for analysis. The mobile phase consisted of 50 mM phosphate solution (containing 300 mM sodium chloride, 30 mM disodium hydrogen phosphate dodecahydrate, and 20 mM sodium dihydrogen phosphate dihydrate, prepared in ultrapure water), pH 6.8 ± 0.2. The relative percentages of the main peak, aggregates, and fragments were calculated using area normalization. The pretreatment and testing methods for the reference sample were the same as for the sample. The test parameters are shown in Table 3 below:

[0209] Table 3 SEC-HPLC purity test parameters

[0210] (b) R-CE-SDS (reduced sodium dodecyl sulfate capillary electrophoresis) detection of the molecular weight of the antibody includes the following steps: rCE-SDS purity detection using a capillary electrophoresis instrument (Maurice instrument). Take a diluent (1wt% SDS + 40mM phosphate buffer, pH 6.5) to dilute each sample to 1 mg / mL, then take 95μL of the diluted sample and mix it with 5μL of 2-mercaptoethanol in a sample tube, centrifuge at 3000rpm at room temperature for 30s, and then incubate at 70℃ for 15min. After incubation, cool to room temperature and centrifuge at 12000rpm at room temperature for 5min. Take out 75μL of sample solution from the sample tube and transfer it to a 96-well plate to avoid generating bubbles, centrifuge at 1000g at room temperature for 10min, and detect using a capillary electrophoresis instrument (Maurice). The pretreatment method and test method of the reference sample are the same as those of the sample.

[0211] The NR-CE-SDS (non-reduced sodium dodecyl sulfate capillary electrophoresis) method for detecting the molecular weight of antibodies includes the following steps: performing an nrCE-SDS purity test using a capillary electrophoresis instrument (Maurice Instruments). Calculate the diluent and sample volume required to dilute each sample to 1 mg / mL based on a final volume of 100 μL. Then, add the diluent (1 wt% SDS + 40 mM phosphate buffer, pH 6.5), 5.0 μL of 0.25 M NEM (N-ethylmaleimide), and the sample to a 1.5 mL sample tube and mix thoroughly. Centrifuge at 3000 rpm at room temperature for 30 seconds, followed by incubation at 70°C for 5 minutes. After incubation, cool to room temperature and centrifuge at 12000 rpm at room temperature for 5 minutes. Remove 75 μL of sample solution from each sample tube and transfer it to a 96-well plate to avoid bubbles. Centrifuge at 1000 g at room temperature for 10 minutes and detect using a capillary electrophoresis instrument (Maurice Instruments). The pretreatment method and test method of the reference product are the same as those of the sample.

[0212] (c) The isoelectric point of each sample component was determined using a capillary electrophoresis instrument (Maurice Instruments) equipped with an icIEF cartridge. Focusing and separation were achieved by focusing components with different isoelectric points at different locations. The isoelectric point determination procedure included: diluting the sample (reference / test sample) to 1.0 mg / mL with ultrapure water. Mixing 20 μL of the 1.0 mg / mL sample solution and ultrapure water (blank sample) with 80.0 μL of icIEF Master Mix in a sample tube, centrifuging at 10,000 rpm for 5 minutes, and then adding 75.0 μL of the supernatant from the sample tube to a 96-well plate, taking care to avoid bubbles. The plate was then centrifuged at 1000 g for 5 minutes to remove bubbles. Detection was performed using a capillary electrophoresis instrument (Maurice Instruments). The pretreatment and testing methods for the reference sample were the same as for the sample. Focusing and separation were achieved by focusing components with different isoelectric points at different locations. The preparation of the icIEF Master Mix is ​​shown in Table 4 below, and the analytical parameters are shown in Table 5.

[0213] Table 4 icIEF Master Mix Preparation

[0214] Table 5 Sample running method parameters

[0215] (d) ELISA assay for detecting antibody biological activity includes the following steps: using an indirect method, human PD-1 (Human PD-1) and human VEGF (Human VEGF) are used as antigens to coat a 96-well plate, the antibody can bind to Human PD-1 and Human VEGF, Mouse Anti-Human IgG4 Fc-HRP (HRP-labeled mouse anti-human IgG4 (Fc) secondary antibody, manufacturer: Southern Biotech; catalog number: 9200-05) can specifically bind to the antibody bound to the solid-phase antigen (Human PD-1, Human VEGF), and can catalyze TMB (trimethyl borate) to develop a blue color under the action of hydrogen peroxide. The depth of the blue color is positively correlated with the amount of Mouse Anti-Human IgG4 Fc-HRP bound, and turns yellow after termination with 2M hydrochloric acid. The absorbance (OD value) is measured at wavelengths of 450 nm / 620 nm using a microplate reader, and the effective binding activity (EC) of the standard curve is calculated. 50 ) to investigate the ability of the dual antibodies to bind to Human PD-1 and Human VEGF, respectively. See Tables 6 and 7 below for details:

[0216] Table 6 Antibody binding PD-1 ELISA experimental method

[0217] Table 7 Antibody binding VEGF ELISA experimental method

[0218] The reporter gene method for detecting the biological activity of antibodies includes the following steps:

[0219] (1) VEGF end: Vascular endothelial growth factor (VEGF), also known as vascular permeability factor (VPF), is a highly specific vascular endothelial cell growth factor that promotes increased vascular permeability, extracellular matrix degeneration, vascular endothelial cell migration, proliferation and angiogenesis. The high-affinity receptor that VEGF specifically binds to is called vascular endothelial growth factor receptor (VEGFR), which is mainly divided into three types: VEGFR-1, VEGFR-2, and VEGFR-3. VEGFR-1 and VEGFR-2 are mainly distributed on the surface of tumor vascular endothelium and regulate the formation of tumor blood vessels; VEGFR-3 is mainly distributed on the surface of lymphatic endothelium and regulates the formation of tumor lymphatic vessels. This application uses target cells 293VEGFR2 and recombinant VEGF (R&D systems, cat#11066-HNAB) protein that overexpress VEGFR2 and the luciferase reporter gene system to detect the biological activity of antibody cells. Target 293VEGFR2 cells were seeded at 50,000 cells per well in a 96-well flat-bottom white plate (corning, cat#3917). A serial dilution of the test antibody (final concentration: 10.2 pM to 66.7 nM) was added at 25 μL / well. VEGF protein was then diluted to a working concentration of 25 ng / mL and incubated at 37°C for 5-6 hours. Finally, luciferase substrate One-Lite (Vazyme, cat#DD1203-03-AB) was added at 40 μL / well and chemiluminescence was detected.

[0220] (2) PD-1 end: NFAT is a key transcription factor for downstream signaling activated by the T cell receptor and is crucial for IL-2 secretion and T cell proliferation response. Antibodies can specifically bind to PD-1 on the cell surface, blocking the PD-1 / PD-L1 interaction, thereby activating the downstream NFAT signaling pathway. The system of this application includes two cell lines: Jurkat PD-1 effector cells (purchased from Promega), which stably express human PD-1 and a luciferase reporter gene coupled to NFAT on Jurkat cells; and CHO PDL1 target cell line (purchased from Promega), which stably expresses CD3 scFv and human PDL1 on CHO-K1 cells. When PD-1 on the surface of the effector cell binds to PDL1 on the surface of the target cell, the NFAT signaling pathway is inhibited and the expression of the luciferase reporter gene coupled thereto is inhibited. Antibodies can specifically bind to PD-1, blocking the PD-1 / PDL1 interaction, thereby activating the downstream NFAT signaling pathway. The detection scheme of this application is as follows: on the first day, target cells PD-L1 aAPC / CHO-K1 cells were cultured at a rate of 5×10 4 The cells were plated at 1×10 cells / well and cultured overnight in a cell culture incubator. The next day, the experimental antibody (final concentration was 7.6 pM to 500 nM) was prepared and added to the cell plate at 40 μL / well. 5 Effector cells PD-1 effector cells were added to each well; the cells were cultured in a 37° C., 5% (volume fraction) CO 2 incubator for 4-6 hours; luciferase substrate was added at 40 μL / well, the plate was read with a multifunctional microplate reader, and data analysis was performed.

[0221] The test results showed that the purity (SEC-HPLC method, R-CE-SDS (reducing electrophoresis method), NR-CE-SDS (non-reducing electrophoresis method), icIEF) and biological activity of the three bispecific antibody molecules did not change significantly, and they had good long-term stability. The specific results are shown in Table 8.

[0222] Table 8 Stability of bispecific antibodies at 5°C for 4 weeks

[0223] Note: “ / ” means not determined, and “ND” means not determined.

[0224] 3. Serum stability of bispecific antibodies

[0225] The bispecific antibody sample was replaced with a pH 5.0 buffer system (20mM histidine-histidine hydrochloride buffer, 230mM sucrose). The bispecific antibody sample concentration was controlled at approximately 10mg / mL. The sample was then diluted to 1mg / mL with human serum and dispensed into vials at a rate of 500μL / vial. The vials were then placed in a 37°C incubator and stability was examined at 0, 2, and 4 weeks. The biological activity of the antibody was tested by ELISA and reporter gene assays. The specific detection methods are the same as those described in "2. Long-term stability of bispecific antibodies" above.

[0226] The test results showed that after being placed at 37°C for 4 weeks, the biological activities of the serum stability samples of Antibody 23, Antibody 24 and Antibody 27 did not change significantly, and they had good serum stability. The specific results are shown in Table 9.

[0227] Table 9 Bispecific Antibody Serum Stability Samples Stability at 37°C for 4 Weeks

[0228] Note: “ / ” means not determined.

[0229] Example 3: Determination of kinetic parameters of bispecific antibodies

[0230] 1. Determination of kinetic parameters of bispecific antibodies and antigen PD-1

[0231] The molecular interaction analyzer Octet RED96e (Sartorius) was used to capture 5 μg / mL JS001 (recombinant humanized anti-PD-1 monoclonal antibody reference product, prepared by Suzhou Junmeng Biopharmaceutical Technology Co., Ltd. according to the antibody sequence of the generic name Toripalimab, wherein the amino acid sequence of LC is shown in SEQ ID NO: 31 and the amino acid sequence of HC is shown in SEQ ID NO: 32), antibody 23, antibody 24, antibody 27, and antibody 28, respectively, and bound to 210 nM and 70 nM recombinant human PD-1 (prepared by Suzhou Junmeng Biopharmaceutical Technology Co., Ltd. according to the sequence of NCBI GenBank: NM_005018) to detect the binding and dissociation kinetic signals. The analysis software Octet Data Analysis 12.0 was used to fit the binding and dissociation curves and calculate the affinity K. D value.

[0232] The specific results are shown in Figures 3a-3e and Table 10. Figure 3a shows the binding and dissociation curves of antibody JS001 and human PD-1; Figure 3b shows the binding and dissociation curves of antibody 23 and human PD-1; Figure 3c shows the binding and dissociation curves of antibody 24 and human PD-1; Figure 3d shows the binding and dissociation curves of antibody 27 and human PD-1; and Figure 3e shows the binding and dissociation curves of antibody 28 and human PD-1. Figures 3a-3e and Table 10 show that antibodies JS001, 23, 24, 27, and 28 all bind to human PD-1 with similar affinities. These results indicate that bispecific antibodies 23, 24, 27, and 28 all maintain the affinity of their original anti-PD-1 monoclonal antibody, JS001.

[0233] Table 10 Binding and dissociation data of JS001 and Antibody 23, Antibody 24, Antibody 27, and Antibody 28 molecules with human PD-1

[0234] 2. Determination of Kinetic Parameters of Bispecific Antibodies and VEGFA

[0235] The molecular interaction analyzer Octet RED96e was used to capture 5 μg / mL DotAb4 (the DotAb4 sequence was obtained from DotBio and expressed. The amino acid sequence of DotAb4 is shown in SEQ ID NO: 33, i.e. The bold underlined portion is the VHH sequence targeting VEGF). Antibodies 23, 24, and 27 were bound to 50 nM and 25 nM recombinant human VEGFA (purchased from Sino Biological, Cat. No. 11066-HNAB), respectively, to detect binding and dissociation kinetic signals. 5 μg / mL antibody 28 was captured using the Octet molecular interaction analyzer and bound to 25 nM and 12.5 nM VEGFA to detect binding and dissociation kinetic signals. The analysis software Octet Data Analysis 12.0 was used to fit the binding and dissociation curves and calculate the affinity K. D value.

[0236] The specific results are shown in Figures 4a to 4e and Table 11, wherein Figure 4a is a graph showing the binding and dissociation curves of antibody DotAb4 and human VEGFA; Figure 4b is a graph showing the binding and dissociation curves of antibody 23 and human VEGFA; Figure 4c is a graph showing the binding and dissociation curves of antibody 24 and human VEGFA; Figure 4d is a graph showing the binding and dissociation curves of antibody 27 and human VEGFA; and Figure 4e is a graph showing the binding and dissociation curves of antibody 28 and human VEGFA. As can be seen from Figures 4a to 4e and Table 11, antibodies DotAb4, 23, 24, 27, and 28 all have strong binding activity to human VEGFA, and their K values ​​are 0.D All were less than 0.5 nM; the above results indicate that bispecific antibodies 23, 24, 27, and 28 all maintained the affinity of their original anti-VEGFA nanobody DotAb4.

[0237] Table 11 Binding and dissociation data of DotAb4, Antibody 23, Antibody 24, Antibody 27, Antibody 28 and human VEGFA

[0238] 3. Activity determination of bispecific antibodies binding to PD-1 and VEGFA simultaneously

[0239] The ability of bispecific antibody 27 to simultaneously bind to two target antigens, human PD-1 and human VEGFA, was tested using the Biacore T200 molecular interaction analyzer (GE Healthcare Life Sciences). The assay involved conjugating a 20 μg / mL anti-mouse Fc fragment antibody to capture the mouse Fc-tagged PD-1 antigen. For the antibody 27 test sample group, which tested the ability of antibody 27 to simultaneously bind to PD-1 and VEGFA, 2 μg / mL of PD-1 was first captured, followed by injection of 100 nM antibody 27, and finally 80 nM human VEGFA or Biacore system buffer (HBS-EP+) (10 mM HEPES buffer, 150 mM sodium chloride, 3 mM EDTA, 0.05 vol% detergent Surfactant P20). Binding signal generated by human VEGFA was detected, representing the binding of antibody 27 to PD-1 followed by subsequent binding to VEGFA. A negative control group was also established. 2 μg / mL PD-1 was first captured, followed by injection of buffer, and finally by injection of 80 nM human VEGFA or buffer. Human VEGFA was detected to generate binding signals to determine whether VEGFA binds nonspecifically to PD-1. Another negative control group was also established. 2 μg / mL PD-1 was first captured, followed by injection of 100 nM anti-PD-1 monoclonal antibody JS001, and finally by injection of 80 nM human VEGFA or buffer. Human VEGFA was detected to generate binding signals to determine whether VEGFA binds nonspecifically to the anti-PD-1 antibody region.

[0240] The specific results are shown in Figures 5a-5c and Table 12. Figure 5a shows the results of antibody 27 in the test sample group binding to both human PD-1 and human VEGFA; Figure 5b shows the results of nonspecific binding of human VEGFA to human PD-1 in the negative control group; and Figure 5c shows the results of nonspecific binding of human VEGFA to JS001 in the negative control group. As can be seen from Figures 5a-5c and Table 12, for the test sample group, the binding signal generated by VEGFA was 41.2 RU, indicating that bispecific antibody 27 can bind to both human PD-1 and human VEGFA simultaneously; the signals generated by VEGFA in the two negative control groups were only 1.0 RU or 1.5 RU, indicating that VEGFA does not nonspecifically bind to the PD-1 antigen or the Fab or Fc regions of the anti-PD-1 antibody JS001.

[0241] Table 12 Simultaneous binding data of antibody 27 to human PD-1 and human VEGFA

[0242] Example 4: ELISA to detect the binding activity of bispecific antibodies to antigens

[0243] 1. ELISA method to detect the binding of bispecific antibodies to antigen PD-1

[0244] Human PD-1 was diluted to 0.3 μg / mL using PBS (manufacturer: Hyclone, catalog number: SH30256.01), added to the ELISA plate at 100 μL / well, and allowed to coat in a 37°C constant temperature incubator for 90 min; the plate was washed; 200 μL / well of 2% BSA (bovine serum albumin, 2% is 1 g BSA plus 50 mL PBS) was added to the plate, and the plate was incubated in a 37°C constant temperature incubator for 90 min; the plate was washed; the sample was diluted to 1000 ng / mL with 2% BSA, and then diluted to 0.0419 ng / mL in a 2.5-fold gradient. All samples were added to the ELISA plate at 100 μL / well and incubated in a 37°C constant temperature incubator for 60 min; the plate was washed; horseradish peroxidase (HRP)-conjugated mouse anti-human IgG4 antibody (manufacturer: Southern Biotech, catalog number: 9200-05) (Fc specific) was diluted 5000 times with 2% BSA and added to the ELISA plate at 100 μL / well and incubated in a 37°C constant temperature incubator for 60 min; the plate was washed; the color development solution TMB (trimethyl borate, manufacturer: Sigma, catalog number: T2885) 0.1 mg / mL was added at 100 μL / well, avoiding bubbles, and the color was developed at 37°C in the dark for 15 min; finally, 2 M hydrochloric acid solution was added to terminate the reaction at 100 μL / well, avoiding bubbles, and the microplate reader was read within 10 min (detection wavelength 450 nm; reference wavelength 620 nm), and the EC was obtained using a four-parameter logarithmic regression (4PL) model.50 (half-maximal effect concentration).

[0245] The specific results are shown in Figures 6a and 6b and Table 13, wherein Figure 6a is an ELISA curve of the binding of antibody 23 and antibody 24 to human PD-1 (EC 50 6.929nM, 14.55nM, and 3.605nM, respectively); Figure 6b is an ELISA curve of the binding of antibody 27 and antibody 28 to human PD-1 (EC 50 The results were as follows: 23.79nM, 59.48nM, and 18.31nM, respectively; TAB001 (i.e., JS001) served as the control group. As can be seen from Figures 6a and 6b and Table 13, bispecific antibodies 23, 24, 27, and 28 all had good binding activity to human PD-1.

[0246] Table 13 Binding data of Antibody 23, Antibody 24, Antibody 27, Antibody 28 molecules to human PD-1

[0247] Note: TAB001 (JS001) data were used as a control.

[0248] 2. ELISA to detect the binding of bispecific antibodies to antigen VEGFA

[0249] Recombinant human VEGFA (manufacturer: Sino Biological, catalog number: 11066-HNAB) was diluted to 0.5 μg / mL in PBS (manufacturer: Hyclone, catalog number: SH30256.01), added to the ELISA plate at 100 μL / well, and incubated in a 37°C incubator for 90 min. The plate was washed; 200 μL / well of 2% BSA was added to the plate and incubated in a 37°C incubator for 90 min. The plate was washed; the sample was diluted to 1000 ng / mL with 2% BSA and then diluted three-fold to 0.0056 ng / mL. All samples were added to the ELISA plate at 100 μL / well and incubated in a 37°C constant temperature incubator for 60 min; the plate was washed; horseradish peroxidase (HRP)-conjugated mouse anti-human IgG4 antibody (manufacturer: Southern Biotech, catalog number: 9200-05) (Fc specific) was diluted 5000 times with 2% BSA and added to the ELISA plate at 100 μL / well, and incubated in a 37°C constant temperature incubator for 60 min; the plate was washed; the color development solution TMB (manufacturer: Sigma, catalog number: T2885) 0.1 mg / mL was added at 100 μL / well, avoiding bubbles, and the color was developed at 37°C in the dark for 15 min; finally, 2 M hydrochloric acid solution was added to terminate the reaction at 100 μL / well, avoiding bubbles, and the microplate reader was read within 10 min (detection wavelength 450 nm; reference wavelength 620 nm), and the EC was obtained using a four-parameter logarithmic regression (4PL) model. 50 .

[0250] The specific results are shown in Figures 7a and 7b and Table 14, wherein Figure 7a is an ELISA curve of the binding of antibody 23 and antibody 24 to human VEGFA (EC 50 7b is the ELISA curve of the binding of antibody 27, antibody 28 and human VEGFA (EC 50 The results were as follows: 6.624 nM, 6.166 nM, and 3.544 nM, respectively; Avastin (bevacizumab, a recombinant humanized anti-VEGF monoclonal antibody; manufacturer: Roche) served as the control group. As can be seen from Figures 7a and 7b and Table 14, bispecific antibodies 23, 24, 27, and 28 all exhibited strong binding activity to human VEGFA.

[0251] Table 14 ELISA data of antibody 23, antibody 24, antibody 27, and antibody 28 binding to human VEGFA

[0252] Note: Avastin data was used as a control.

[0253] 3. Competitive ELISA to determine the activity of bispecific antibodies in competing with VEGFR2 for binding to the antigen VEGFA

[0254] Recombinant human VEGFA (manufacturer: Sino Biological, catalog number: 11066-HNAB) was diluted to 0.5 μg / mL with PBS (manufacturer: Hyclone, catalog number: SH30256.01), added to the ELISA plate at 100 μL / well, and incubated in a 37°C constant temperature incubator for 90 minutes; the plate was washed; 200 μL / well 2% BSA was added to the plate, and the plate was incubated in a 37°C constant temperature incubator for 90 minutes; the plate was washed; VEGFR2 His tag-biotinylated (manufacturer: Sino Biological, catalog number: 10012-H08H-B) was diluted to 0.3 μg / mL with 2% BSA, and the sample was diluted to 100,000 ng / mL with 0.3 μg / mL of VEGFR2 His tag-biotinylated, and then diluted to 0.56 ng / mL in a 3-fold gradient. All samples were added to the ELISA plate at 100 μL / well and incubated in a 37°C constant temperature incubator for 60 min; the plate was washed; horseradish peroxidase (HRP)-conjugated Streptavidin (manufacturer: Jackson ImmunoResearch, catalog number: 016-030-084) was diluted 5000-fold with 2% BSA and added to the ELISA plate at 100 μL / well and incubated in a 37°C constant temperature incubator for 60 min; the plate was washed; the color development solution TMB (manufacturer: Sigma, catalog number: T2885) 0.1 mg / mL was added at 100 μL / well, avoiding bubbles, and the color was developed at 37°C in the dark for 15 min; finally, 2 M hydrochloric acid solution was added to terminate the reaction at 100 μL / well, avoiding bubbles, and the microplate reader was read within 10 min (detection wavelength 450 nm; reference wavelength 620 nm). The IC was obtained using a four-parameter logarithmic regression (4PL) model. 50 (half inhibitory concentration).

[0255] The specific results are shown in Figures 8a, 8b and Table 15, wherein Figure 8a is an ELISA curve of competitive inhibition of antibody 23 and antibody 24 against human VEGFR2 and VEGFA (IC 50 8b is a graph showing the competitive inhibition of antibody 27 and antibody 28 in blocking human VEGFR2 and VEGFA by ELISA (IC values ​​of antibody 27, antibody 28, and Avastin are 679.4nM, 1076nM, and 660.7nM, respectively); FIG. 8b is a graph showing the competitive inhibition of antibody 27 and antibody 28 in blocking human VEGFR2 and VEGFA by ELISA (IC values ​​of antibody 27, antibody 28, and Avastin are 679.4nM, 1076nM, and 660.7nM, respectively). 50As can be seen from Figures 8a, 8b and Table 15, bispecific antibodies 23, 24, 27 and 28 can effectively block the binding of human VEGFR2 to human VEGFA.

[0256] Table 15 Competitive inhibition ELISA data of antibodies 23, 24, 27, and 28 blocking human VEGFR2 and VEGFA

[0257] Note: Avastin data was used as a control.

[0258] 4. Competitive ELISA method to determine the activity of bispecific antibodies in competing with PD-L1 for binding to antigen PD-1

[0259] Human PD-1 (manufacturer: Suzhou Junmeng) was diluted to 1.5 μg / mL in PBS (manufacturer: Hyclone, catalog number: SH30256.01). 100 μL / well of the microtiter plate was added and the plate was coated in a 37°C incubator for 90 minutes. The plate was washed. 200 μL / well of 2% BSA was added to the plate and the plate was incubated in a 37°C incubator for 90 minutes. The plate was washed. Biotin-PD-L1 hFc was diluted to 4.0 μg / mL with 2% BSA. The sample was then diluted to 100,000 ng / mL with 4.0 μg / mL of Biotin-PD-L1 hFc and then diluted in a 3-fold series to 0.56 ng / mL. All samples were added to the ELISA plate at 100 μL / well and incubated in a 37°C constant temperature incubator for 60 min; the plate was washed; horseradish peroxidase (HRP)-conjugated Streptavidin (manufacturer: Jackson ImmunoResearch, catalog number: 016-030-084) was diluted 5000-fold with 2% BSA and added to the ELISA plate at 100 μL / well and incubated in a 37°C constant temperature incubator for 60 min; the plate was washed; the color development solution TMB (manufacturer: Sigma, catalog number: T2885) 0.1 mg / mL was added at 100 μL / well, avoiding bubbles, and the color was developed at 37°C in the dark for 15 min; finally, 2 M hydrochloric acid solution was added to terminate the reaction at 100 μL / well, avoiding bubbles, and the microplate reader was read within 10 min (detection wavelength 450 nm; reference wavelength 620 nm). The IC was obtained using a four-parameter logarithmic regression (4PL) model. 50 .

[0260] The specific results are shown in Figures 9a and 9b and Table 16, wherein Figure 9a is an ELISA curve of competitive inhibition of antibody 23 and antibody 24 blocking human PD-L1 and PD-1 (IC 509b is the competitive inhibition ELISA curve of antibody 27 and antibody 28 blocking human PD-L1 and PD-1 (IC 50 As can be seen from Figures 9a and 9b and Table 16, bispecific antibodies 23, 24, 27, and 28 can effectively block the binding of human PD-L1 to human PD-1.

[0261] Table 16 Competitive inhibition ELISA data of antibodies 23, 24, 27, and 28 blocking human PD-L1 and PD-1

[0262] Note: TAB001 (JS001) data were used as a control.

[0263] Example 5. Cellular Functional Activity of Bispecific Antibodies

[0264] 1. Activity detection of bispecific antibodies in the PD-1 / PD-L1 luciferase reporter gene system

[0265] Target cells CHO PD-L1 (human PD-L1 and CD3 scFv stably expressed on CHO cells, purchased from Promega) were plated in a 96-well white flat-bottom plate at a rate of 5 × 10 4 The cells were plated overnight; the next day, after the culture medium in the cell wells was aspirated, different concentrations of bispecific antibodies or control antibodies (starting concentration was 500nM, 4-fold dilution, a total of 9 concentration gradients) were added to the target cells using experimental buffer (RPMI 1640 culture medium (1×) + 1% FBS (fetal bovine serum)) and incubated at 37°C for 30 minutes. Then, effector cells Jurkat PD-1 (stable expression of human PD-1 and luc2P / NFAT-RE on Jurkat cells, purchased from Promega) were added at 1×10 per well. 5 The cells were added to the cell plate and incubated in a 37°C incubator for 6 hours. Finally, ONE-Lite luciferase detection reagent (Vazyme, Cat#1203-03) was added to the cell-antibody mixture, and the chemiluminescent signal was detected using a multifunctional microplate reader (TECAN M1000 pro). The EC was calculated by fitting a four-parameter regression curve using GraphPad Prism software. 50 The positive control was JS001 (recombinant humanized anti-PD-1 monoclonal antibody).

[0266] The results are shown in Figures 10a and 10b, where Figure 10a shows the activity test results of antibodies 23 and 24 in the PD-1 / PD-L1 luciferase reporter gene system; Figure 10b shows the activity test results of antibodies 27 and 28 in the PD-1 / PD-L1 luciferase reporter gene system. It can be seen from Figures 10a and 10b that antibodies 23 (IgG4), 24 (IgG4), 27 (IgG4), 28 (IgG4) and JS001 can effectively activate the activity of T cells in the above reporter gene system, and EC 50 The activity of antibody 23 and antibody 24 were better than JS001, and the activity of antibody 27 was comparable to that of JS001.

[0267] 2. Activity detection of bispecific antibodies blocking VEGF-induced NFAT signaling in a luciferase reporter gene system

[0268] The target cells 293VEGFR2 (stable expression of VEGFR2 (KDR) and NFAT-RE-luc 2p, purchased from China Food and Drug Administration) were plated in 96-well white flat-bottom plates at a rate of 1×10 5 Cells were plated; different concentrations of bispecific antibodies or control antibodies (starting at 66.7 nM, 3-fold dilution, a total of 10 concentration gradients) were added to the target cells using experimental buffer (DMEM medium + 2% FBS). VEGF antigen (Sino Biological, Cat#11066-HNAB, working concentration of 30 ng / mL) was then added to the cell plate and incubated in a 37°C incubator for 5 hours; finally, ONE-Lite luciferase detection reagent (Vazyme, Cat#1203-03) was added to the cell-antibody mixture, and the chemiluminescent signal was detected using a multi-function microplate reader (TECAN M1000 pro). The four-parameter regression curve was fitted using GraphPad prism software to calculate the IC 50 The positive control was Avastin (chemical name "bevacizumab", a recombinant humanized anti-VEGF monoclonal antibody).

[0269] The results are shown in Figures 11a and 11b, wherein Figure 11a is a graph showing the activity detection results of the luciferase reporter gene system in which antibodies 23 and 24 blocked VEGF-induced NFAT signaling (IC values ​​of antibodies 23, 24, and Avastin). 5011b is a graph showing the activity detection results of antibody 27 and antibody 28 blocking VEGF-induced NFAT signal in the luciferase reporter gene system (IC 50 As can be seen from Figures 11a and 11b, Antibody 23, Antibody 24, Antibody 27, and Antibody 28 can all specifically bind to the VEGF antigen, thereby blocking the binding of the VEGF protein to its receptor, and further blocking the downstream signaling pathway, thereby inhibiting tumor-induced angiogenesis. The activities of Antibody 24 and Antibody 28 are comparable to those of Avastin, while Antibody 23 is more active than Avastin.

[0270] 3. Experiment on the inhibition of VEGFA-induced HUVEC cell proliferation by bispecific antibodies

[0271] VEGF antigen (working concentration of 10 ng / mL) was plated in a 96-well white plate. Different concentrations of bispecific antibody or control antibody (bispecific antibody starting concentration of 10 nM, 3-fold dilution, a total of 10 concentration gradients; control antibody starting concentration of 66.7 nM, 3-fold dilution, a total of 10 concentration gradients) were added to the 96-well white plate using culture medium and the antibody and antigen were co-incubated in a 37°C incubator for 0.5 hours. HUVEC cells (purchased from Shanghai Aoneng Biotechnology Co., Ltd.) were then plated at 3×10 per well. 3 Cells were plated into 96-well white plates and incubated at 37°C for 96 hours. Finally, Cell counting-Lite luciferase detection reagent (Vazyme, cat#DD1101-03) was added to the cell-antibody-antigen mixture, and the chemiluminescent signal was detected using a multifunctional microplate reader (TECAN M1000 pro). GraphPad Prism software was used to fit a four-parameter regression curve and calculate the IC 50 The positive control was Avastin.

[0272] The results are shown in Figures 12a and 12b, wherein Figure 12a is an experimental result diagram of the inhibition of VEGFA-induced HUVEC cell proliferation by antibody 23 and antibody 24 (IC 50 12b is the experimental results of the inhibition of VEGFA-induced HUVEC cell proliferation by antibody 27 and antibody 28 (IC 50103.9 nM, 150.3 nM, and 90.62 nM, respectively. As can be seen from Figures 12a and 12b, Antibodies 23, 24, 27, and 28 are all able to specifically bind to the VEGF antigen, thereby inhibiting HUVEC cell proliferation. Furthermore, the activities of Antibodies 23, 24, and 28 are comparable to those of Avastin. These results demonstrate that the antibodies of the present application can significantly inhibit VEGF-induced HUVEC cell proliferation, thereby inhibiting HUVEC cell angiogenesis, improving tumor-induced angiogenesis, and ultimately achieving the purpose of tumor inhibition.

[0273] 4. Bispecific antibodies promote the secretion of cytokines IFN-γ and IL-2 in mixed lymphocyte reactions

[0274] Commercial human PBMC (purchased from Shanghai Aoneng Biotechnology Co., Ltd.) were purified using CD14 MicroBeads, Human (Miltenyi Biotec, cat#130-050-201) to obtain CD14 cells. The adherent cells were then stimulated with 10 ng / mL GM-CSF (Sino Biological, cat#GMP-11846-HNAE) and 10 ng / mL IL-4 (Sino Biological, cat#GMP-10015-HNAH) for 5 days, and then stimulated with 5 ng / mL IL-1β (Sino Biological, cat#10139-HNAE), 10 ng / mL IL-6 (Sino Biological, cat#GMP-10395-HNAE), 10 ng / mL TNF-α (Sino Biological, cat#GMP-10602-HNAE) and 1 μmol / L PGE2 (dinoprostone) for 2 days to induce mature dendritic cells (mDC, donor 1). CD4 T cells (donor 2) were obtained by purifying commercial human PBMC using CD4 T MicroBeads, Human (Miltenyi Biotec, cat# 130-045-101).

[0275] Test antibodies were co-incubated with mDCs (10,000 cells per well) and purified CD4 T cells (100,000 cells per well) at varying concentrations (starting at 150 nM, followed by 10-fold dilutions, for a total of four concentrations) in a 96-well round-bottom plate in a 37°C CO2 incubator for 5 days. On day 3 of incubation, aliquots of the reaction supernatants were collected from each well of the 96-well plate and assayed for IL-2 release using the BD CBA human IL2 Flex set (BD, cat#558270). On day 5 of incubation, IFN-γ levels were assayed using the BD CBA human IFNγ Flex set (BD, cat#558269). Positive controls included Ref1 (ivonescimab, a recombinant humanized anti-PD-1 and VEGF bispecific antibody from Kangfang Biopharma; AK112, synthesized based on the INN published sequence (INN Number: 11809)).

[0276] The results are shown in Figures 13a-13d, where Figure 13a shows the experimental results of antibodies promoting IL-2 secretion in a mixed lymphocyte reaction with donor 1; Figure 13b shows the experimental results of antibodies promoting IL-2 secretion in a mixed lymphocyte reaction with donor 2; Figure 13c shows the experimental results of antibodies promoting IFN-γ secretion in a mixed lymphocyte reaction with donor 1; and Figure 13d shows the experimental results of antibodies promoting IFN-γ secretion in a mixed lymphocyte reaction with donor 2. As can be seen from Figures 13a-13d, antibodies 23, 24, 27, and 28, as well as the positive control antibody Ref1, all promoted the release of IL-2 and IFN-γ in the mixed lymphocyte reaction, indicating that they can activate immune cells by relieving the inhibition of PD-1, restoring immune cell function, and thus killing tumor cells.

[0277] Example 6: In vivo efficacy of bispecific antibodies

[0278] The inhibitory effects of antibodies 23 and 27 of the present application on the B-hPD-1 mouse transplanted MC38 model.

[0279] Female B-hPD-1 humanized mice aged 6-8 weeks (purchased from Biocytogen Jiangsu Gene Biotechnology Co., Ltd.) were subcutaneously inoculated on the right side with 1×10 6 MC38 cells (purchased from Nanjing Kebai Biotechnology Co., Ltd.). The average tumor volume was about 116 mm 3Appropriate animals were selected and randomly divided into five groups according to tumor volume, with six animals in each group. These groups were: G1 saline control group (solvent control group); G2 JS001 (1 mg / kg) group; G3 DotAb4 (0.56 mg / kg) group; G4 Antibody 23 (1.25 mg / kg) group; and G5 Antibody 27 (1.25 mg / kg) group.

[0280] Intraperitoneal injection, once every other day, for 9 consecutive doses, the experiment was terminated 2 days after the last dose. Tumor volume and body weight were measured twice a week, and the weight and tumor volume of the mice were recorded. At the end of the experiment, the mice were euthanized and the tumor inhibition rate TGI (%) was calculated. TGI (%) = [1-(Ti-T0) / (Vi-V0)] × 100% (Ti: mean tumor volume of the treatment group on the i-th day of administration, T0: mean tumor volume of the treatment group on the 0th day of administration; Vi: mean tumor volume of the solvent control group on the i-th day of administration, V0: mean tumor volume of the solvent control group on the 0th day of administration).

[0281] The results are shown in Table 17 and Figure 14, where Figure 14 shows the inhibitory effect of the test substance on the B-PD-1 humanized mouse transplanted MC38 tumor model, and Table 17 shows the efficacy analysis table of each group in the B-PD-1 humanized mouse transplanted MC38 tumor model (18 days after the start of administration). It can be seen from Table 17 and Figure 14 that on the 18th day after administration, the average tumor volume of the normal saline control group was 1815±98.7mm 3 The average tumor volume of the JS001 (1 mg / kg) group was 702 ± 7.72 mm 3 Compared with the saline control group, the tumor inhibition rate was 65.5%, which significantly inhibited tumor growth; the average tumor volume of the DotAb4 (0.56 mg / kg) group was 968±15.01 mm 3 Compared with the normal saline control group, the tumor inhibition rate was 49.9%, showing a slight tumor inhibition effect. The average tumor volume of the antibody 23 (1.25 mg / kg) and antibody 27 (1.25 mg / kg) groups was 687 mm 3 and 505mm 3 Compared with the saline control group, the tumor inhibition rates were 66.4% and 77.1%, respectively, significantly inhibiting tumor growth.

[0282] Table 17 Analysis of drug efficacy of each group in the B-PD-1 humanized mouse transplanted MC38 tumor model

[0283] Note: 1. Data are expressed as "mean ± standard error". "-" indicates absence.

[0284] 2.TGI%=[1-(Ti-T0) / (Vi-V0)]×100%;

[0285] 3. P values ​​were obtained by comparing the tumor volumes of each group using the T test method.

[0286] Example 7: In vivo efficacy of bispecific antibodies

[0287] The antibody 27 of the present application has an inhibitory effect on the A375 melanoma model transplanted in NDG mice.

[0288] A375 human malignant melanoma cells and Matrigel were mixed at a volume ratio of 1:1, and 0.2 mL (containing 5×10 6 A375 human malignant melanoma cells were inoculated subcutaneously on the right back of NDG mice (purchased from Biocytogen Jiangsu Gene Biotechnology Co., Ltd.) and the tumors were grown to approximately 137 mm. 3 0.2 mL (containing 10×10 6 Peripheral blood mononuclear cells (PBMCs) were purchased from Shanghai Aoneng Biotechnology Co., Ltd. (Cat. No. LP220829009). Two days later, 24 human PBMCs were randomly divided into six groups based on tumor volume, with four mice per group. These groups included: G1 saline control, G2 Avastin (16.7 mg / kg), G3 Ref1 (22.2 mg / kg), G4 Antibody 27 (5 mg / kg), G5 Antibody 27 (10 mg / kg), and G6 Antibody 27 (20 mg / kg).

[0289] All animals were intraperitoneally injected with the drug, twice a week, for a total of 6 times. Tumor volume and body weight were measured twice a week, and the weight and tumor volume of the mice were recorded. At the end of the experiment (i.e., on the 21st day after administration), the mice were euthanized and the tumor inhibition rate TGI (%) was calculated. TGI (%) = [1-(Ti-T0) / (Vi-V0)] × 100% (Ti: mean tumor volume of the treatment group on the i-th day of administration, T0: mean tumor volume of the treatment group on the 0th day of administration; Vi: mean tumor volume of the solvent control group on the i-th day of administration, V0: mean tumor volume of the solvent control group on the 0th day of administration).

[0290] The results are shown in Table 18 and Figure 15, where Figure 15 shows the inhibitory effect of the test substance on the A375 tumor model transplanted in NDG immunodeficient mice, and Table 18 shows the efficacy analysis of each group in the A375 tumor model transplanted in NDG immunodeficient mice (21 days after the start of administration). As can be seen from Table 18 and Figure 15: The average tumor volume of the G2 Avastin (16.7 mg / kg) group was 398±164 mm 3The tumor inhibition rate was 41.7%. The average tumor volume of the G3 Ref1 (22.2 mg / kg) group was 350±149.2 mm 3 The tumor inhibition rate was 53.0%. The average tumor volume of the G4 antibody 27 (5 mg / kg) group was 321 ± 79.3 mm 3 The tumor inhibition rate was 59.8%. The average tumor volume of the G5 antibody 27 (10 mg / kg) group was 206±76.7 mm 3 The tumor inhibition rate was 86.7%. The average tumor volume of the G6 antibody 27 (20 mg / kg) group was 195 ± 80.1 mm 3 The tumor inhibition rate was 89.0%. G6 antibody 27 (20 mg / kg) was more effective than G3 Ref1 (22.2 mg / kg), significantly inhibiting tumor growth compared with the saline group (P < 0.05).

[0291] Table 18 Analysis of drug efficacy of each group in the NDG immunodeficient mouse transplanted A375 tumor model

[0292] Note: 1. Data are expressed as "mean ± standard error". "-" indicates absence.

[0293] 2.TGI%=[1-(Ti-T0) / (Vi-V0)]×100%;

[0294] 3. P values ​​were obtained by comparing the tumor volumes of each group using the T test method.

[0295] Example 8. Pharmacokinetics of bispecific antibodies in cynomolgus monkeys

[0296] Female cynomolgus monkeys (animal source: Guangxi Fangchenggang Changchun Biotechnology Development Co., Ltd.; use license number: SCXK Gui 2018-0005) were given a single intravenous drip of 5 minutes with different code-named bispecific antibodies, namely antibody Ref1 (ivonescimab, Kangfang Bio's recombinant humanized anti-PD-1 and VEGF bispecific antibody, AK112), antibody 23, and antibody 27, at a dose of 3 mg / kg, two per group, and about 1 mL of whole blood samples were collected at 0 minutes (before administration), 5 minutes (end of drip), 1 hour, 6 hours, 24 hours, 48 ​​hours, 72 hours, 144 hours, 168 hours, 240 hours, 336 hours, and 504 hours. After the whole blood sample naturally coagulated, the serum was separated and stored for blood drug concentration detection. The specific detection method is as follows:

[0297] Human / Cynomolgus VEGF / VEGFA / VEGF165 Protein (Sino Biological, 11066-HNAB) was diluted to 0.3 μg / mL and coated onto a 96-well plate at 100 μL / well and blocked with 2 wt% BSA. The standard curve (4000 ng / mL (anchor point), 2000 ng / mL, 1000 ng / mL, 500 ng / mL, 250 ng / mL, 125 ng / mL, 62.5 ng / mL, 31.3 ng / mL, and 15.6 ng / mL (anchor point)), quality control points (HQC (1600 ng / mL), MQC (400 ng / mL), LQC (100 ng / mL)), and test samples (diluted to within the standard curve range) were uniformly diluted 20-fold with 2 wt% BSA and added to the plate at 100 μL / well. Then, human PD-1his diluted with 2 wt% BSA was added. A 0.2 μg / mL ELISA tag (homemade) was added to the plate at 100 μL / well. The detection antibody was an anti-his tag antibody (HRP) diluted in 2 wt% BSA to 0.1 μg / mL and added to the plate at 100 μL / well. Then, 100 μL / well of tetramethylbenzidine (TMB) was added, and the reaction was terminated with 2 M hydrochloric acid. The absorbance (OD) was measured at 450 nm / 620 nm using a microplate reader, and sample concentrations were calculated using SoftMax Pro 5.4.1 software.

[0298] The drug concentrations and metabolic kinetic parameters in the serum of each group of animals are summarized in Tables 19 and 20. (0-t) It refers to the area enclosed by the blood drug concentration curve on the time axis; t 1 / 2z Refers to the endpoint blood drug concentration and its half-life; T max V refers to the time to peak, which is the time required to reach the peak concentration of the drug after administration; z Refers to the apparent distribution volume, the proportional constant between the amount of drug in the body and the blood concentration when the drug reaches dynamic equilibrium in the body; Cl z Refers to the clearance rate; C max It refers to the peak drug concentration, the highest blood drug concentration after administration.

[0299] Table 19 Summary of drug concentrations in serum of each group

[0300] Table 20 Pharmacokinetic parameters of each group

[0301] As can be seen from Table 20, after a single intravenous infusion of the test drug at a dose of 3 mg / kg into female cynomolgus monkeys, the AUC(0-t) of Antibody 27, Antibody 23, and Antibody ref1 (Kangfang) were 152.7±95.2 μg / mL×d, 141.7±37.0 μg / mL×d, and 113.5±25.1 μg / mL×d, respectively, indicating that a higher exposure level can be achieved after administration. The half-life t 1 / 2z The elimination efficiencies of antibody 27 and antibody 23 were 0.9±0.3 days, 1.0±0.2 days, and 1.6±0.2 days, respectively, which were comparable to those of conventional bispecific antibodies, indicating that the drug had good drugability. z It is about 20-50mL / kg, indicating that the drug is mainly in the circulation after intravenous injection in monkeys and no extravascular distribution occurs.

[0302] The above description is only a preferred embodiment of the present application and is not intended to limit the present application. Any modifications, equivalent replacements, improvements, etc. made within the spirit and principles of the present application shall be included in the scope of protection of the present application.

Claims

1. A bispecific antibody comprising a first protein functional region and a second protein functional region; wherein: The first protein functional region is an anti-PD-1 antibody or an antigen-binding fragment thereof, the second protein functional region is an anti-VEGF antibody or an antigen-binding fragment thereof, the anti-VEGF antibody or the antigen-binding fragment thereof comprises a heavy chain variable region, and the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 whose amino acid sequences are shown in SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9, respectively.

2. The bispecific antibody according to claim 1, wherein The anti-PD-1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region and / or a light chain variable region; the amino acid sequences of HCDR1, HCDR2 and HCDR3 contained in the heavy chain variable region are respectively selected from the amino acid sequences of HCDR1, HCDR2 and HCDR3 contained in the heavy chain variable region of nivolumab, pembrolizumab, cemiprilimumab, toripalimab, sintilimab or carrelizumab; the amino acid sequences of LCDR1, LCDR2 and LCDR3 contained in the light chain variable region are respectively selected from the amino acid sequences of LCDR1, LCDR2 and LCDR3 contained in the light chain variable region of nivolumab, pembrolizumab, cemiprilimumab, toripalimab, sintilimab or carrelizumab.

3. The bispecific antibody according to claim 1 or 2, wherein the anti-PD-1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region and / or a light chain variable region, wherein the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, respectively, and the light chain variable region comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6, respectively.

4. The bispecific antibody according to any one of claims 1 to 3, wherein The anti-PD-1 antibody or antigen-binding fragment thereof comprises: a heavy chain variable region having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence shown in SEQ ID NO: 10, and a light chain variable region having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence shown in SEQ ID NO: 11; and / or The anti-VEGF antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the amino acid sequence shown in SEQ ID NO:

12.

5. The bispecific antibody according to any one of claims 1 to 3, wherein The anti-PD-1 antibody or antigen-binding fragment thereof is selected from Fab, Fab', F(ab')2, Fd, Fv, dAb, complementarity determining region fragment, single domain antibody, single chain antibody, humanized antibody, chimeric antibody or diabody; and / or The anti-VEGF antibody or antigen-binding fragment thereof is selected from Fab, Fab', F(ab')2, Fd, Fv, dAb, complementarity determining region fragment, single domain antibody, single chain antibody, humanized antibody, chimeric antibody or diabody.

6. The bispecific antibody according to any one of claims 1 to 5, wherein The first protein functional region is an immunoglobulin, and / or The second protein functional region is a single domain antibody.

7. The bispecific antibody according to claim 6, wherein The immunoglobulin is selected from IgG, IgA, IgD, IgE or IgM; preferably IgG.

8. The bispecific antibody according to claim 6, wherein The constant region of the immunoglobulin is derived from a human antibody; Preferably, the constant region of the immunoglobulin is selected from the constant region of human IgG1, IgG2, IgG3 or IgG4.

9. The bispecific antibody according to claim 6, wherein There are two single-domain antibodies, and one end of each single-domain antibody is connected to the C-terminus or N-terminus of the two heavy chains of the immunoglobulin respectively; or One end of each of the single-domain antibodies is connected to the C-terminus or N-terminus of the two light chains of the immunoglobulin; or The N-terminus of each single-domain antibody is respectively connected to the C-terminus of the heavy chain constant region CH1 of the immunoglobulin, and the C-terminus of each single-domain antibody is respectively connected to the N-terminus of the heavy chain constant region CH2 of the immunoglobulin.

10. The bispecific antibody according to claim 9, wherein (1) The first polypeptide chain of the bispecific antibody is represented by the formula VLPD-1-CL, and the second polypeptide chain is represented by the formula VHVEGF-linker-VHPD-1-CH1-hinge-CH2-CH3; or (2) the first polypeptide chain of the bispecific antibody is represented by the formula VLPD-1-CL, and the second polypeptide chain is represented by the formula VHPD-1-CH1-hinge-CH2-CH3-linker-VHVEGF; or (3) the first polypeptide chain of the bispecific antibody is represented by the formula VLPD-1-CL, and the second polypeptide chain is represented by the formula VHPD-1-CH1-linker-VHVEGF-linker-hinge-CH2-CH3; or (4) The first polypeptide chain of the bispecific antibody is represented by the formula VHVEGF-linker-VLPD-1-CL, and the second polypeptide chain is represented by the formula VHPD-1-CH1-hinge-CH2-CH3.

11. The bispecific antibody according to claim 10, wherein (1) the first polypeptide chain comprises the amino acid sequence shown in SEQ ID NO: 13, and the second polypeptide chain comprises the amino acid sequence shown in SEQ ID NO: 14; or (2) the first polypeptide chain comprises the amino acid sequence shown in SEQ ID NO: 13, and the second polypeptide chain comprises the amino acid sequence shown in SEQ ID NO: 15; or (3) the first polypeptide chain comprises the amino acid sequence shown in SEQ ID NO: 13, and the second polypeptide chain comprises the amino acid sequence shown in SEQ ID NO: 16; or (4) The first polypeptide chain comprises the amino acid sequence shown in SEQ ID NO: 17, and the second polypeptide chain comprises the amino acid sequence shown in SEQ ID NO:

18.

12. An isolated nucleic acid molecule encoding the bispecific antibody of any one of claims 1 to 11.

13. A vector comprising the isolated nucleic acid molecule of claim 12.

14. A host cell comprising the isolated nucleic acid molecule of claim 12, or the vector of claim 13. 15 . A method for preparing the bispecific antibody according to claim 1 , comprising the steps of culturing the host cell according to claim 14 , and obtaining the bispecific antibody from the culture.

16. A conjugate comprising the bispecific antibody according to any one of claims 1 to 11 and a conjugated moiety, wherein: The coupling part is a therapeutically active substance or a detectable label; preferably, the therapeutically active substance is a cytotoxin, a cytokine or a radionuclide; preferably, the detectable label is selected from a radioisotope, a fluorescent substance, a luminescent substance, a colored substance or an enzyme.

17. A kit comprising the bispecific antibody according to any one of claims 1 to 11, or the conjugate according to claim 16; Preferably, the kit further comprises a second antibody, which is capable of specifically binding to the bispecific antibody; preferably, the second antibody further comprises a detectable label, and more preferably, the detectable label is selected from a radioactive isotope, a fluorescent substance, a luminescent substance, a colored substance or an enzyme.

18. A pharmaceutical composition comprising the bispecific antibody according to any one of claims 1 to 11 or the conjugate according to claim 16; preferably, the pharmaceutical composition further comprises a pharmaceutically acceptable excipient.

19. A method for treating or ameliorating a malignant tumor, comprising administering the bispecific antibody according to any one of claims 1 to 11, the conjugate according to claim 16, or the pharmaceutical composition according to claim 18 to a patient in need thereof, wherein: The malignant tumor is a tumor that overexpresses PD-L1 and / or VEGF; preferably, the malignant tumor is a solid tumor; more preferably, the malignant tumor is lung cancer, colon cancer, colorectal cancer, melanoma or ovarian cancer; more preferably, the lung cancer is non-small cell lung cancer or small cell lung cancer; more preferably, the non-small cell lung cancer is squamous non-small cell lung cancer or non-squamous non-small cell lung cancer; more preferably, the non-squamous non-small cell lung cancer is locally advanced or metastatic non-squamous non-small cell lung cancer.

20. A method for regulating immune response and regulating tumor angiogenesis, comprising administering the bispecific antibody according to any one of claims 1 to 11 or the conjugate according to claim 16 or the pharmaceutical composition according to claim 18 to a patient in need; preferably, the regulating immune response is achieved by blocking the binding of PD-1 to its receptor, and the regulating tumor angiogenesis is achieved by blocking the binding of VEGF to its receptor.

Citation Information

Patent Citations

  • Vegfa-binding molecules

    CN117242092A

  • Anti-PD-1-anti-VEGF bispecific antibody, pharmaceutical composition and application thereof

    CN119039450A

  • DD110103A1

  • DD120303A1

  • Recombinant immunoglobin preparations

    US4816567A

Cited By

  • Bispecific Anti-PD-1 x Anti-VEGF-a for the treamtent of metastatic non-small cell lung cancer

    WO2026206973A1

  • Biomarkers and methods for tumor therapy

    WO2026208876A1

  • Pharmaceutical composition comprising Anti-PD-1 / VEGF bispecific antibody and use thereof

    WO2026214643A1